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                                                                            ABSTRACT
Spasticity is a feature of altered skeletal muscle performance in muscle tone involving 
hypertonia; it is also referred to as an unusual "tightness", stiffness, or "pull" of muscles
palsy and spinal. Spasticity, a condition in which certain muscles are continuously
contracted, affects over 12 million worldwide. Baclofen is the largest prescribed drug
for this indication, worldwide. Even though once-daily extended release GRS is available
in the market, it is very expensive as it is a coated multi-layer gas generating floating tablet.
The main objective is to develop once-daily sustained release gastro-retentive floating
system of Baclofen in an economical way by using HPMC and natural gums. Fourteen 
formulations of floating matrix tablets of Baclofen (F1 – F14) were prepared by using 
different polymers and additives (HPMC K100M, HPMC K15M, HPMC K4M, Guar gum 
Xanthan gum PEO WSR301,- 303, sodium bicarbonate, Avicel PH-102, Talc, Magnesium 
stearate) at  different concentrations by direct compression method.  The formula 11 was 
found to be optimum and released 98.47% of Baclofen in 24hrs. . Hence, it was selected as
the optimized formulation. Marketed formulation exhibited FLT of 63.67±4.01 seconds,
TFT of 24 hours and released 95.07±0.41% drug in 24 hours. Finally, once-daily
sustained release gastro-retentive floating tablets of Baclofen were successfully
formulated in a relatively economical way when compared to the marketed  formulation 
and found to be superior when compared to the  marketed formulation.
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INTRODUCTION
INTRODUCTION
MODIFIED RELEASE ORAL DRUG DELIVERY SYSTEMS:
The oral route represents nowadays the predominant and most preferable route for drug 
delivery. Unlike the majority of parenteral dosage forms, it allows ease of administration 
by the patient and it’s the natural, and therefore a highly convenient way for substances to 
be introduced into the human body.
Oral drug delivery systems (DDS) are mainly immediate release (conventional) drug 
delivery systems which are intended to disintegrate rapidly, and exhibit instant drug 
release. They are associated with a fast increase and decrease, and hence fluctuations in 
drug plasma levels, which leads to reduction or loss in drug effectiveness or increased 
incidence of side effects. Administration of the DDS several times per day is therefore 
necessary to compensate the decrease in drug plasma concentration due to metabolism and 
excretion leading to poor patient compliance.
In order to overcome the drawbacks associated with conventional drug delivery systems, 
several technical advancements have led to the development of Modified release systems 
that could revolutionize method of medication and provide a number of therapeutic 
benefits.
Modified release systems, have been developed to improve the pharmacokinetic profiles 
of active  pharmaceutical ingredients (APIs) and patient compliance(reducing the 
frequency of dosing), as well as reducing the side effects[1-3].Oral modified release 
delivery systems are most commonly used for 1) delayed release (e.g., by using an enteric 
coating); 2) extended release (e.g., zero-order, first-order, biphasic release, etc.); 3) 
programmed release (e.g., pulsatile, triggered, etc.) and 4) site specific or timed release
(e.g., for colonic delivery or gastric retention). Extended, sustained or prolonged release 
drug delivery systems are terms used synonymously to describe this group of controlled 
drug delivery devices, with  predictability and reproducibility in the drug release 
kinetics[4]. Delayed release dosage forms are distinguished from the ones mentioned 
above as they exhibit a pronounced lag time before the drug is released. Oral extended 
release dosage forms offer the opportunity to provide constant or nearly constant drug
plasma levels over an extended period of time following administration[5]. Two basic types 
of extended release dosage forms are designed to generate temporal input profile for drug
delivery[6].
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Matrix systems: It consists of rate controlling polymer, which is uniformly dissolved or 
dispersed with drug.
Reservoir system: This type of system separates drug compartment from polymer membrane 
that permits a diffusion barrier to yield drug flux of either zero order or first order.
Extended release DDS offer several advantages compared to conventional DDS
including[7]:
i. Avoiding drug level fluctuations by maintenance of optimal therapeutic plasma and 
tissue concentrations over prolonged time periods, avoiding sub-therapeutic as well as 
toxic concentrations, thus minimizing the risk of failure of the medical treatment and 
undesirable side effects;
ii. Reducing the administered dose while achieving comparable effects;
iii. Reduced frequency of administration leading to improved patient compliance and 
subsequently improved efficacy of the therapy and cost effectiveness;
iv. Targeting or timing of the drug action.  Hence, it is highly desirable to develop
sustained DDS releasing the drug at predetermined rates to achieve optimal drug levels at 
the site of action.
On the other hand, drugs administered as sustained or extended release oral dosage form 
should comply with the following parameters:
i. Maintain a constant plasma level over prolonged time periods;
ii. Have a broad therapeutic window to avoid health hazard to the patient in case of 
undesirable burst release of the nominal dose[8].
Using current release technology, oral delivery for 24 hours is possible for many drugs 
but the drug should have good absorption throughout the gastrointestinal tract (GIT), 
preferably by passive diffusion, to ensure continuous absorption of the released drug. A 
major constraint in oral controlled drug  delivery  is that not all drug candidates are 
absorbed uniformly throughout the GIT. Such drugs are said to have an absorption
window i.e., absorbed only from specific areas of the GIT, principally due to their low
Permeability or solubility in the intestinal tract, their chemical instability, the binding of
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the drug to the gut contents, as well as to the degradation of the drug by the 
microorganisms present in the colon[9-12]. Therefore, in instances where the drug is not 
absorbed uniformly over the G.I tract, the rate of drug absorption may not be constant 
inspite of the drug delivery system delivering the drugs at a constant rate into the G.I
fluids. More particularly, in instances where a drug has a clear cut absorption window 
(the drug is absorbed only from specific regions of the GIT like the stomach or upper 
parts of the small intestine), it may not be completely absorbed leading to unpredictable 
bioavailability and times to achieve peak plasma levels when administered in the form of
a typical oral controlled drug delivery system. It is due to the relatively brief gastric 
emptying in humans, which normally averages 2-3 hrs through the major absorption zone. 
It may cause incomplete drug release from the dosage form at absorption sites leading to 
diminished efficacy of the administered dose. It is apparent that for a drug having such an 
absorption window, an effective oral controlled drug delivery system should be designed 
not only to deliver the drug at a controlled rate, but also to retain the drug in the stomach 
for a long period of time. For this drug, increased or more predictable availability would 
result if controlled release systems could be retained in the stomach for extended periods 
of time.
GASTRO-RETENTIVE DRUG DELIVERY SYSTEMS:
Dosage forms that can be retained in the stomach for prolonged and predictable period of 
time are called gastro-retentive drug delivery systems (GRDDS).The retention of oral 
dosage forms  in  the upper GIT causes  prolonged  contact  time of drug with  the GI 
mucosa, leading to higher bioavailability, and hence therapeutic efficacy, reduced time 
intervals for drug administration, potentially reduced dose size and thus improved patient
compliance[13]. Therefore, extended / sustained release DDS possessing gastric retention
Properties may be potentially useful[14] .
Basic Gastrointestinal Tract Physiology:
To comprehend the considerations taken in the design of gastric retention dosage forms 
and to evaluate their performance the relevant anatomy and physiology of the G.I tract
must be fully understood.
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Anatomically the stomach is divided into 3 regions: fundus, body, and antrum 
(pylorus)(Fig.1.1). The proximal part made of fundus and body acts as a reservoir for 
undigested material, whereas the antrum is the main site for mixing motions and act as a 
pump for gastric emptying by propelling actions[15].
Fig 1.1: Anatomy of the stomach
Gastric emptying occurs during fasting as well as fed states. The pattern of motility is 
however distinct in the 2 states. During the fasting state an inter-digestive series of 
electrical events take place, which cycle both through stomach and intestine every 2 to 3 
hours[16]. This is called the inter-digestive myoelectric cycle or migrating myoelectric 
cycle (MMC), which is further divided into following 4 phases as described by Wilson
and Washington[17] (Fig.1.2).
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Fig 1.2: Inter-digestive myoelectric cycle (MMC)
 Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions.
 Phase II (pre-burst phase) lasts for 40 to 60 minutes with intermittent action potential 
and contractions. As the phase progresses the intensity and frequency also increases 
gradually.
 Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and regular 
contractions for short period. It is due to this wave that all the undigested material is 
swept out of the stomach down to the small intestine. It is also known as the 
housekeeper wave.
 Phase IV lasts for 0 to 5 minutes and occurs between phases III and I of 2 consecutive 
cycles. After the ingestion of a mixed meal, the pattern of contractions changes from 
fasted to that of fed state. This is also known as digestive motility  pattern and 
comprises continuous contractions as in phase II of fasted state. These contractions 
result in reducing the size of food particles (to less than 1 mm), which are propelled 
toward the pylorus in a suspension form. During the fed state onset of MMC is 
delayed resulting in slowdown of gastric emptying rate[18].
Requirements for Gastro-retention:
From the discussion of the physiology of the stomach, to achieve gastro-retention, the 
dosage form must satisfy some requirements. One of the key issues is that the dosage 
form must be able to withstand the forces caused by peristaltic waves in the stomach and
constant grinding and churning mechanisms (phase III). It must resist premature gastric
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emptying and once the purpose has been served, it should be removed from the stomach 
with ease.
Factors controlling gastric retention of dosage forms
The gastric retention time (GRT) of dosage forms is controlled by several factors such as:
Density of dosage form:
Dosage forms having a density lower than that of gastric fluid experience floating 
behavior and hence gastric retention. A density of <1.0 gm/cm3  is required to exhibit 
floating property. However, the floating tendency of the dosage form usually decreases as 
a function of time, as the dosage form gets immersed into the fluid, as a result of the 
development of hydrodynamic equilibrium[19].
Size of dosage form:
The size of the dosage form is another factor that influences gastric retention. The mean 
gastric residence times of non-floating dosage  forms are highly variable and  greatly 
dependent on their size, which may be small, medium, and large units. In fed conditions, 
the smaller units get emptied from the stomach during the digestive phase and the larger 
units during the housekeeping waves. In most cases, the larger the size of the dosage
form, the greater will be the gastric retention time[20] because the larger size would not
allow the dosage form to quickly pass through the pyloric antrum into the intestine. Thus 
the size of the dosage form appears to be an important factor affecting gastric retention.
Food intake and nature of food:
Food intake, the nature of the food, caloric content, and frequency of feeding have a 
profound effect on the gastric retention of dosage forms. The presence or absence of food 
in the stomach influences the GRT of the dosage form. Usually, the presence of food 
increases the GRT of the dosage form and increases drug absorption by allowing it to stay 
at the absorption site for a longer time. In a gamma scintigraphic study of a bilayer
floating capsule of misoprostol[21], the mean gastric residence time was 199 ± 69 minutes;
after a light breakfast, a remarkable enhancement of average GRT to 618 ± 208 minutes 
was observed. The above results are supported by the experiments of Whitehead et al.[22]
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which show an increase in the relative heights of the floating units after meal 
consumption.
Effect of gender, posture and age:
A study by Mojaverian et.al.[23] found that females showed comparatively shorter mean 
ambulatory GRT than males, and the gastric emptying in women was slower than in men. 
The authors also studied the effect of posture on GRT, and found no significant difference 
in the mean GRT for individuals in upright, ambulatory and supine state. On the other 
hand, in a comparative study in humans by Gansbeke et.al.[24] the floating and non-
floating systems behaved differently. In the upright position, the floating systems floated 
to the top of the gastric contents and remained for a longer time, showing prolonged 
GRT. But the non-floating units settled to the lower part of the stomach and underwent
faster emptying as a result of peristaltic contractions, and the floating units remained 
away from the pylorus.
Since many factors could lead to alterations in gastric emptying process, which may 
seriously affect the release of a drug from its delivery system, it is therefore, desirable to 
develop a DDS that exhibits an extended GI residence and a drug release profile 
independent of patient related variables.
APPROACHES TO GASTRO- RETENTION
Various approaches have been pursued to increase the retention of an oral dosage form in 
the stomach. These systems mainly include: Floating/Buoyant systems, Bio-adhesive
systems, Swelling and expanding systems, High density systems(Fig.1.3).
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Fig 1.3: Approaches to gastro-retention
Bio/Muco-adhesive Systems:
Bio/muco-adhesive systems are those which bind to the gastric epithelial cell surface or 
mucin and serve as a potential means of extending the GRT of drug delivery system in the 
stomach, by increasing the intimacy and duration of contact of drug with the biological 
membrane.
The surface epithelial adhesive properties of mucin have been well recognized and 
applied to the development of GRDDS based on bio/muco-adhesive polymers.
Limitation of these systems is the gastric epithelial mucin turnover, which effects the 
reproducibility of these systems.
Swelling and Expanding Systems :
These are the dosage forms, which after swallowing; swell to an extent(12-18 mm in their 
expanded state) that prevents their exit from the pylorus. As a result, the dosage form is 
retained in the stomach for a long period of time. These systems may be named as “plug 
type system”, since they exhibit the tendency to remain logged at the pyloric sphincter. 
The formulation is designed for gastric retention and controlled delivery of the drug into 
the gastric cavity. Such polymeric matrices remain in the gastric cavity for several hours
even in the fed state. A balance between the extent and duration of swelling is maintained
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by the degree of cross-linking between the polymeric chains. A high degree of cross-
linking retards the swelling ability of the system maintaining its physical integrity for 
prolonged period.
Limitation of this system is, it requires certain period of time for swelling of these 
systems during which they can be emptied from the stomach.
High Density Systems:
These systems with a density of about 3g/cm3 are retained in the rugae of the stomach and 
are capable of withstanding its peristaltic movements. A density of 2.6-2.8 g/cm3 acts as a 
threshold value after which such systems can be retained in the lower part of the stomach. 
High-density formulations include coated pellets. Coating is done by heavy inert material
such as barium sulphate, zinc oxide, titanium dioxide, iron powder etc.
Limitation: These systems remain close to the pyloric splincter, which may result in 
gastric emptying of these systems.
Floating Drug Delivery/ Hydrodynamically balanced Systems (FDDS/ HBS):
Floating systems, first described by Davis in 1968[25], are low-density systems that have a 
density of less than 1 g/ml, to float over the gastric contents and remain in the stomach for 
a prolonged period. While the system floats over the gastric contents, the drug is released 
slowly at the desired rate, which results in increased GRT and reduces fluctuation in 
plasma drug concentration. This system is shown in Fig.1.4.
Fig 1.4: Graphic of Buoyant tablet, which is less dense than the stomach fluid and 
therefore remains in the fundus.
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Advantages of FDDS[26]:
 Sustained Drug Delivery: Sustained drug absorption from oral controlled release 
dosage form is often limited due to short gastric retention time. However, FDDS 
remain in the stomach for several hours to increase their GRT. Thus, prolongation in 
the GRT results in sustained drug release at the absorption site.
 Absorption or Bioavailability Enhancement: FDDS enhances the bioavailability of 
active agent by, beneficially altering its absorption.
 Site Specific Drug Delivery: FDDS greatly improve stomach pharmacotherapy 
through local drug release, which leads to high drug concentrations at the gastric 
mucosa making it possible to treat duodenal ulcers, gastritis and oesophagitis, and 
reduce the risk of gastric carcinoma.
 Carriers: FDDS can be used as carriers for drugs such as antiviral, antifungal and 
antibacterial agents which are taken up only from very specific site of gastrointestinal 
tract (GIT). These drugs are said to have absorption window.
 Patient Compliance: FDDS have been recommended to improve patient compliance 
and convenience due to less frequent drug administration and the nature of the drug's 
release kinetics.
 Fewer side effects: FDDS show a decrease in total adverse effects with improved 
absolute bioavailability of the drug due to reduction of fluctuation in drug blood 
concentration and maximum utilization of the drug.
 Improved plasma levels: An increased safety margin of highly potent drugs can be 
achieved by formulating them as FDDS, due to better control of plasma concentration 
and expulsion of the floating system from the stomach after complete release of the 
drug which reduced suppression of the drug's activity  by  the body  (i.e. counter 
activity) and minimized adverse activity at the colon.
 FDDS provide maintenance of systemic drug concentration within the therapeutic 
window, and provide site specific drug delivery. Drugs with absorption sites in the
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upper small intestine, such as furosemide and riboflavin can be typically formulated using 
this system.
Limitations of FDDS[26]:
 The major disadvantage of floating systems is requirement of a sufficiently high 
level of fluids in the stomach for the drug delivery i.e. upto 400ml of gastric fluids 
should be present for optimum buoyancy In order to keep these tablets floating 
in-vivo, intermittent administration of water is beneficial, as the ability to float 
relies on the hydration state of the dosage form.
 The drugs that have solubility or stability problems in the gastric fluid and may 
cause irritation to gastric mucosa cannot be formulated as FDDS.
 Drugs which are well absorbed along the entire GIT and which undergo 
significant first pass metabolism, may not be formulated as FDDS since the slow 
gastric emptying may lead to reduced systemic bioavailability.
Suitable Drug Candidates for FDDS include[26]:
 Drugs acting locally in the stomach. Ex: Antacids, misoprostol and drugs used 
eradication of H.pylori, (the causative organism for chronic gastritis and peptic 
ulcer) Ex:Tetracycline.
 Drugs with a narrow window of absorption from the stomach and upper part of the
GIT. Ex: Riboflavin and Levodopa.
 Drugs having stability at the acidic environment of the stomach and non-irritant to 
the gastric mucosa.
 Drugs that have low solubility at high pH values. Ex:Verapamil
 Drugs that are unstable in the intestine or colonic environment. Ex: Ranitidine.
 Drugs that disturb normal colonic bacteria. Ex: Amoxicillin trihydrate.
Drugs that are unsuitable for FDDS[26]:
  Drugs that have very limited acid solubility (e.g. phenytoin).
  Drugs that suffer instability in the gastric environment (e.g. erythromycin).
 Drugs intended for selective release in the colon [e.g. 5-amino salicylic acid,
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corticosteroids]
1.1 Types   of floating drug   delivery   systems (FDDS)[26]:
Based on the mechanism of buoyancy, two distinctly different technologies have been 
utilized in development of FDDS which are:
1.1.1. Effervescent System, and
1.1.2. Non- Effervescent System.
1.1.1 Effervescent System:
These effervescent systems further classified into two types.
1.1.1.1. Gas Generating systems
1.1.1.2.Volatile Liquid Containing Systems.
1.1.1.1. Gas – Generating Systems:
These are matrix type of systems prepared with the help of hydrophilic swellable 
polymers such as Hydroxy propyl methylcellulose, polysaccharides and various 
effervescent compounds, e.g., sodium bicarbonate, tartaric acid, and citric acid. They 
are formulated in such a way that when in contact with the acidic gastric contents, 
CO2     is liberated and gets entrapped in jellified  hydrocolloids, which provide 
buoyancy to the dosage forms by lowering the density of the dosage forms. The
mechanism of floating of a gas generating system is shown in Fig.1.5.
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Fig1.5: Mechanism of floating systems(GF= Gastric fluid)
F = F buoyancy - F gravity
= (Df - Ds) gv--- (1)
where, F= total vertical force, Df = fluid density,Ds = object density, v = volume and 
g=acceleration due to gravity.
Types of gas generating systems include:
1.1.1.1.1. Intragastric Single Layer Floating Tablets or Hydrodynamically Balanced
System (HBS) [27]:
The system is shown in Fig.1.6 and formulated by intimately mixing the CO2 generating 
agents, drug and the polymer within the matrix tablet. These have a bulk density lower 
than gastric fluids and therefore remain floating in the stomach unflattering the gastric 
emptying rate for a prolonged period. The drug is slowly released at a desired rate from 
the floating system and after the complete release the residual system is expelled from the 
stomach. This leads to an increase in the GRT and a better control over fluctuations in
plasma drug concentration.
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Fig 1.6: Intragastric Single Layer Buoyant Tablet.
1.1.1.1.2. Intragastric Bilayer Floating Tablets [28]:
These are compressed bi-layer tablets containing two layers(Fig.1.7), the gas generating 
mechanism in one hydrocolloid containing layer and the drug in the other 
layer(containing a release controlling polymer) formulated for a SR effect. After contact 
with acidic  aqueous media, CO2    is generated and entrapped within the gelling 
hydrocolloid, causing the system to float; meanwhile the drug was released in a sustained 
manner from the SR layer.
Effervescent layer
Fig 1.7:  Intra Gastric Bilayer Buoyant Tablet
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1.1.1.1.3. Intragastric triple layer Floating Tablets:
A floating dosage form of triple drug regimen was developed by Yang et al. [29] to 
prolong the gastric residence time of triple drug regimen (tetracycline, metronidazole, and
clarithromycin) for the treatment of Helicobacter pylori–associated peptic ulcers. The 
design of the delivery system was based on the swellable asymmetric triple-layer tablet 
approach (Fig.1.8). Two drugs were incorporated into the core layer of the triple-layer 
matrix for controlled delivery, while third drug was included in one of the outer layers for 
instant release. The floatation was accomplished by incorporating a gas-generating layer 
consisting of sodium bicarbonate: calcium carbonate (1:2 ratios) along with the polymers.
Figure1.8: Schematic presentation of working of a triple-layer system. (A) Initial 
configuration of triple-layer tablet. (B) On contact with the dissolution medium the 
bismuth layer rapidly dissolves and matrix starts swelling. (C) Tablet swells and 
erodes. (D) and (E) Tablet erodes completely.
1.1.1.1.4. Multiple Unit type floating pills:
This system was developed by Ichikawa et al.[30] The system consisted of sustained 
release pills as seeds surrounded by double layers (Fig.1.9). The inner layer was a double 
effervescent  layer containing both  NaHCO3  and  tartaric acid  to avoid direct  contact 
between sodium bicarbonate and tartaric acid. The outer layer was a swellable membrane 
layer containing mainly PVA and purified shellac. Following contact with aqueous
media, it formed swollen balloon like pills, with a density much lower than 1 g/ ml, due to
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the carbon dioxide generated by the neutralization reaction in the inner effervescent layers 
with the diffusion of water through the outer swellable membrane layer. The system was 
found to float completely within 10 minutes and approximately 80% remained floating 
over a period of 5 h irrespective of pH and viscosity of the test medium. Meanwhile, the 
drug was released.
Fig 1.9: A multi-unit oral buoyant dosage system. Stages of floating mechanism: (A) 
penetration of water; (B) generation of CO2 and floating; (C) dissolution of drug. 
Key: (a) conventional SR pills; (b) effervescent layer; (c) swellable layer; (d) 
expanded swellable membrane layer; (e) surface of water in the beaker (370C)
1.1.1.2. Volatile Liquid containing Systems:
 Intragastric Osmotically Controlled Drug Delivery System[31,32]:
The system comprises of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly 
disintegrates to release the intragastric osmotically controlled drug delivery device. The 
inflatable support inside contains gases with a boiling point < 37°C (e.g., cyclopentane, 
diethyl ether) incorporated in solidified or liquefied form. At physiological temperatures, 
the liquid that gasifies at body temperature to inflate the bag.  The osmotic pressure 
controlled drug delivery device consists of two components; drug reservoir compartment 
and an osmotically active compartment.
The drug reservoir compartment is enclosed by a pressure responsive collapsible bag, 
which is impermeable to vapour and liquid and has a drug delivery orifice. The
osmotically active compartment contains an osmotically active salt and is enclosed within
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a semipermeable housing. In the stomach, the water in the GI fluid is continuously 
absorbed through the semi permeable membrane into osmotically active compartment to 
dissolve the osmotically active salt. An osmotic pressure is thus created which acts on the 
collapsible bag and in turn forces the drug reservoir compartment to reduce its volume 
and activate the drug release through the delivery orifice.
The floating  support is also made to contain a bioerodible plug  that erodes after a 
predetermined time to deflate the support. The deflated drug delivery system is then 
emptied from the stomach. This system is shown in Fig 1.10.
Fig1.10: Intragastric Osmotically Controlled Drug Delivery System
1.1.2 Non-Effervescent systems: [33]
The approach involved in the formulation of floating dosage forms is intimate mixing of 
drug with a gel forming hydrocolloid, which swells in contact with gastric fluid after oral 
administration and maintains a relative integrity of shape and a bulk density of less than 
unity within  the outer gelatinous  barrier.  The air  entrapped  by the swollen polymer 
confers buoyancy to these dosage forms. The gel structure acts as a reservoir for sustained 
drug release since the drug is slowly released  by a controlled diffusion through the 
gelatinous barrier. Commonly used excipients, here are gel-forming or highly swellable 
cellulose type hydrocolloids, polysaccharides and matrix forming polymers such as
polycarbonate, polyacrylate, polymethacrylate and polystyrene.
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The limitation of this approach is that floating concept in an HBS is rather passive, i.e., it 
mainly depends on the air captured into the dry mass inside the hydrating gelatinous 
surface layer. Because of this passivity, the buoyancy of an HBS largely depends on the 
characteristics and amount of hydrophilic polymers used.
This system can be further divided into four sub-types:
1.1.2.1 Colloidal gel barrier system:
Sheth and Toussounian[34] developed a HBS capsule containing a mixture of a drug and 
hydrocolloids. Upon contact with gastric fluids, the capsule shell dissolves and the 
mixture swells and forms a gelatinous barrier thereby remaining buoyant in the gastric 
juice for an extended period of time. Pharmaceutical products, using the same principle, 
containing  APIs  have been  developed,  containing  L-DOPA,  combined  with  a 
decarboxylase inhibitor. This system is shown in Fig.1.11.
Fig 1.11: Colloidal gel barrier system
1.1.2.2 Microporous compartment system:
A multiple-unit gastro-retentive DDS which contained air compartments was developed 
by Iannuccelli et al.[35].The units forming  the system were composed of a calcium
alginate core separated by an air compartment from a membrane of calcium alginate or
PGPCOPS & RI.  NAMAKKAL. Page 18
INTRODUCTION
calcium alginate/ polyvinyl acetate (PVA). In the stomach, the floatation chamber 
containing entrapped air causes the delivery system to float over the gastric content. 
Gastric fluid enters through the aperture, dissolves the drug and carries the dissolved drug 
for continuous transport across the intestine for absorption.
1.1.2.3 Alginate Beads:
Whitehead et al. [36] developed multiple unit floating freeze dried calcium alginate beads 
of approximately 2.5 mm diameter by dropping a sodium alginate solution into aqueous 
solution of  calcium  chloride, causing precipitation of calcium alginate leading to 
formation of porous system. These beads maintained a positive floating force for over 12 
hrs.
1.1.2.4 Hollow Microspheres:
Hollow microspheres (micro balloons) (Fig.1.12), loaded with drug in their outer polymer 
shells were prepared by a novel emulsion-solvent diffusion method [37]. The ethanol: 
dichloromethane solution of the drug and an enteric acrylic polymer was poured into an 
agitated aqueous solution of PVA that was thermally controlled at 400C. The gas phase 
generated in dispersed polymer droplet by evaporation of dichloromethane formed an 
internal cavity in microsphere of polymer with drug. The micro balloons floated 
continuously over the surface of acidic dissolution media containing surfactant for more 
than 12 hours in-vitro.
Fig 1.12: Hollow microspheres
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Table1.2: Marketed Products of FDDS[26]:
S.NO.
BRAND 
NAME
DRUG (DOSE)
COMPANY, 
COUNTRY
DOSAGE FORM
1. Modular®
Levodopa (100
mg), Benserazide
(25 mg)
Roche Products, USA
Floating CR
capsule
2. Val release® Diazepam (15 mg)
Hoffmann-Larches,
USA
Floating capsule
3. Liquid
Gavison®
Al hydroxide (95 
mg), Mg 
carbonate (358 
mg)
GlaxoSmith Kline, 
India
Effervescent 
floating liquid 
alginate 
preparation
4. Topalkan® Al-Mg antacid
Pierre Fabre Drug, 
France
Floating liquid
alginate 
preparation
5. Conviron Ferrous sulphate Ranbaxy, India
Colloidal gel
forming FDDS
6. Cifran OD®
Ciprofloxacin (500
mg, 1 gm)
Ranbaxy, India
Gas-generating
floating tablet
7. Cytotec®
Misoprostol (100
mcg/200 mcg)
Pharmacia, USA
Bilayer floating
capsule
8. Oflin OD® Ofloxacin (400mg) Ranbaxy, India
Gas generating
floating tablet
9. Baclof OD Baclofen (20 mg)
Intas
Pharmaceuticals,India
Coated multi-layer
gas generating 
floating tablet
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Past work on Baclofen sustained release drug delivery system:
Very few findings were published/ carried out on BCF sustained release drug delivery
system.
• Rishad R. Jivani et al. (2009) [43] developed  a self correcting monolithic gastro-
retentive tablet of Baclofen. PEO WSR-303 was used as the polymer and sodium 
bicarbonate was used as the effervescent agent in the formulation. Tablets were
prepared by direct compression technique. The in-vitro dissolution studies were
carried out using USP XXI type II (Paddle method) Dissolution Rate Test Apparatus 
at 37 + 0.5°C and 50 rpm speed. 900 mL of 0.1N HCl was used as the dissolution 
medium. The tablets successfully sustained the drug release upto 12 hours. The 
optimized formulation exhibited a floating lag time of 120 seconds and a total floating
time of 12 hours. Kinetics of drug release from the tablet followed Korsmeyer –
Peppas model by anamolous non-fickian diffusion.
• Rishad R. Jivani et al. (2010) [44] developed a novel floating In-situ gelling system
for stomach specific drug delivery of the narrow absorption window drug Baclofen.
Sodium alginate-based in-situ gelling systems were prepared by dissolving various 
concentrations of sodium alginate in deionized water, to which varying concentrations 
of drug and calcium bicarbonate were added. The in-vitro dissolution studies were
carried out using USP XXI type II (Paddle method) Dissolution Rate Test Apparatus
at 37 + 0.5°C and 50 rpm speed. 500 mL of 0.1N HCl was used as the dissolution
medium. The tablets successfully sustained the drug release upto 12 hours. The 
floating lag time and floating time of the optimized formulation were found to be 120
seconds and 12 hrs respectively. The drug release from the in-situ gel followed 
Higuchi model, which indicates a diffusion-controlled release.
• Prema R et al. (2010) [45] formulated sustained release matrix tablets of Baclofen for 
treatment of spasticity resulting from multiple sclerosis, flexor spasm and muscular
rigidity. The matrix tablets were prepared by wet granulation method using HPMC 
K4M, K100M and xanthan gum in various concentrations. The in-vitro dissolution
studies were carried out using USP XXI type II (Paddle method) Dissolution Rate
Test Apparatus at 37 + 0.5°C and 50 rpm speed. 900 mL of 0.1N HCl (pH 1.2) was
used as the dissolution medium for the first 2 hrs, followed by pH 6.8 for remaining
period of time. The final formulation B7 (25% HPMC K4M and K100M) extented the
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release of Baclofen upto 12hrs. Model fitting analysis for the final formulation fitted
in the zero order model and Korsemeyer- Peppas model. The ‘n’ values obtained from
the Korsemeyer- Peppas equation suggested that, drug release was non-Fickian 
diffusion mechanism. It was concluded that sustained release matrix tablets of 
Baclofen containing 25% of HPMC K4M and HPMC K100M provide a better option
for sustained release of drug.
• Stephen Rathinaraj B et al. (2010) [46] developed sustained release matrix tablets of 
Baclofen. The matrix tablets were prepared using using hydrophilic swellable 
polymers  (HPMC K15M & guargum) and water insoluble polymer like ethyl
cellulose by employing wet granulation method. The in-vitro release studies were
performed in 0.1 N HCl for first two hours and in 7.4 pH phosphate buffer upto 12 
hours. The final formulation containing 10 % guargum showed better release i.e, 80 –
90 % drug release within l0 -11 hours and successfully sustained the release of drug 
upto 12 hours.
• Gande S et al. (2011) [47] developed sustained release effervescent floating matrix
tablets of Baclofen. Polymers Methocel K100M, Methocel K15M, HPMC E6-LV and
effervescent agent sodium bicarbonate were used in the formulation. Tablets were
prepared by wet granulation technique. The in-vitro dissolution studies were carried 
out using USP XXI type II (Paddle method) Dissolution Rate Test Apparatus at 37 +
0.5°C and 50 rpm speed. 900mL of 0.1N HCl was used as the dissolution medium.
The tablets successfully sustained the drug  release upto 12 hours. The optimized 
formulation exhibited a floating lag time of 180 seconds and a total floating time of
12 hours. For all formulations, kinetics of drug release from tablet followed 
Higuchi’s square root of time kinetic treatment heralding diffusion as predominant 
mechanism of drug release. There was no significant change in the selected 
formulations, when subjected to accelerated stability conditions over a period of three
months.  X-ray studies were investigated. X-ray imaging in six healthy human
volunteers revealed a mean gastric retention period of 5.50±0.7 hrs for the selected
formulation.
• Upendra Kulkarni et al. (2011) [48] fabricated bi-layer matrix tablets of Baclofen
using  ethylcellulose consisting of two layers such as fast releasing layer and
sustaining layer. Fast releasing layer was prepared by using super disintegrant like
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sodium starch glycolate and sustained release layer was prepared by using synthetic
polymer like ethyl cellulose by wet granulation method. The In vitro release studies were
performed in 0.1 N HCl for first two hr and in 7.4 pH phosphate buffer upto 24 hrs. It
was observed that final formulation containing 50% ethyl cellulose successfully
sustained the release of drug upto 24 hours.
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BACLOFEN[39-42]:
Category: Synthetic Antispastic agent or muscle Relaxant.
Chemical Name: 4-amino-3-(4-chlorophenyl)-butanoic acid
Molecular Formula: C10H12Cl NO2
Description:
Baclofen is a white powder to off- white, virtually odorless, crystalline powder with
slightly bitter taste. It has a molecular weight of 213.66. It is slightly soluble in water,
very slightly soluble in ethanol (96 per cent), practically insoluble in acetone. It dissolves
in dilute mineral acids and in dilute solutions of alkali hydroxides.
Chemical Structure:
Dissociation Constant:pKa 3.87
Partition Co-efficient : Log P (octanol/water), 1.3
Clinical Pharmacology:
Indication: For the alleviation of signs and symptoms of spasticity resulting from
multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain,
clonus, and muscular rigidity.
Mechanism of Action:
The precise mechanism of action of Baclofen is not fully known. Baclofen is capable of 
inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by 
hyperpolarization of afferent terminals, although actions at supraspinal sites may also
occur and contribute to its clinical effect. Although Baclofen is an analog of the putative
PGPCOPS & RI.  NAMAKKAL. Page 24
DRUG PROFILE
inhibitory neurotransmitter gamma-amino-butyric acid (GABA), there is no conclusive
evidence that actions on GABA systems are involved in the production of its clinical
effects. In studies  with animals, Baclofen has been shown to have general CNS
depressant properties as  indicated by the production of sedation with   tolerance,
somnolence, ataxia, and respiratory and cardiovascular depression.
Pharmacokinetics:
Absorption: Baclofen is rapidly and extensively absorbed in the upper GIT. Absorption
may be dose-dependent, being reduced with increasing doses. Following a single 20 mg
oral dose, the peak plasma concentration(178 ng/mL) was reached about 0.5-3 hours after
administration.
Distribution: The apparent volume of distribution is 59 liters. Baclofen does not readily 
cross the blood-brain barrier. Plasma protein binding is approximately 30%.
Metabolism: In a study using radiolabeled Baclofen, approximately 85% of the dose was 
excreted unchanged in the urine and feces. About 15% of the dose was metabolized,
primarily by deamination. The γ -hydroxy metabolite, 3-(p-chlorophenyl)-4-
hydroxybutyric acid, is formed after deamination of Baclofen.
Excretion: About 70 to 80% of a dose is excreted in the urine mainly as unchanged drug. 
The remainder is excreted as unchanged drug in the feces or as metabolites in the urine
and faeces. The elimination half-life of Baclofen is approximately 2.5-4 hours.  Total
systemic clearance is 180 mL/min and renal clearance is 103 mL/min.
Pharmacodynamics:
Baclofen is a muscle relaxant and antispastic agent. Baclofen is useful for the alleviation
of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the 
relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Although
Baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric
acid (GABA), there is no conclusive evidence that actions on GABA systems are
involved in the production of its clinical effects. In studies with animals, Baclofen has 
been shown to have general CNS depressant properties as indicated by the production of 
sedation  with  tolerance,  somnolence,  ataxia,  and  respiratory  and  cardiovascular
depression. Baclofen is rapidly and extensively absorbed and eliminated. Absorption may
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be dose-dependent, being reduced with increasing doses. Baclofen is excreted primarily
by the kidney in unchanged form and there is relatively large intersubject variation in 
absorption and/or elimination.
Dosage: Oral: Severe chronic spasticity:
Adult: Initially, 5mg t.i.d for three days followed by 10mg t.i.d three days until 20mg t.i.d 
or desired effect is obtained.
Maximum Daily dose: 100 mg
Child: 0.75-2 mg/kg daily.May initiate with 2.5 mg 4 times daily, increased gradually
every 3 days until desired effect is obtained.
Maintenance: 6-10 yr:30-60mg daily;2-6 yr:20-30  mg daily;12 months-2 yr:10-20 mg
daily.
Elderly: Initiate with lower doses.
Contraindications: Baclofen should not be administered to patients with a history of
Hypersensitivity and Active peptic ulcer disease.
Drug Interactions:
Alcohol and other CNS depressants may exacerbate the CNS effects of Baclofen and 
should be avoided; severe aggravation of hyperkinetic symptoms may possibly occur in
patients taking lithium. There may be increased weakness if Baclofen is given to patients 
taking a tricyclic antidepressant and there may be an increased hypotensive effect if it is
given to patients receiving antihypertensive therapy. Ibuprofen and other drugs that 
produce renal insufficiency may reduce Baclofen excretion leading to toxicity.
Dopaminergics: For reports of patients with Parkinson’s disease taking  levodopa who 
have had adverse effects when given Baclofen.
NSAID’s: There has been a report of an elderly patient who developed Baclofen toxicity 
after ibuprofen therapy was also started. It appeared that acute renal insufficiency caused
by ibuprofen had impaired Baclofen excretion.
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Adverse Drug Reactions:
Adverse effects associated with Baclofen are often transient and dose-related. They may
be minimised by increasing doses gradually or controlled by a reduction in dosage.
The most common  adverse effects include drowsiness, nausea, dizziness, lassitude, 
lightheadedness, confusion, fatigue, muscular pain and weakness, and hypotension. Other 
adverse   effects  include  euphoria,hallucinations,  depression,  headache,  tinnitus, 
convulsions, paraesthesias, slurred speech, dry mouth, taste alterations, vomiting,
diarrhoea or constipation, ataxia, nystagmus, tremors, insomnia, visual disturbances,
skinrashes, pruritus, increased sweating, urinary disturbances, respiratory or 
cardiovascular depression, blood sugar changes, alterations in liver function values, and a 
paradoxical increase in spasticity. Problems with erection and ejaculation have also been
reported with intrathecal Baclofen; these are usually reversible on withdrawal of therapy.
Overdosage:-
Over dosage may lead to muscular hypotonia, hypothermia, drowsiness, respiratory 
depression, coma, and convulsions. Stopping Baclofen abruptly may result in a 
withdrawal syndrome.
Treatment of Baclofen overdosage is symptomatic. Consideration should be given to the 
use of activated charcoal in adults who have ingested more than 100 mg, and children
who have taken more than 5 mg/kg, within an hour of presentation. Alternatively, gastric
lavage may be considered in adults within an hour of ingesting a life-threatening 
overdose. Haemodialysis should be considered in severe cases. Observation should
continue for at least 6 hours after ingestion.
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AIM AND OBJECTIVE:
   Spasticity, a condition in which certain muscles are continuously contracted, affects over
12 million worldwide. Generally, spasticity is associated with common neurological 
disorders like multiple sclerosis, stroke, cerebral palsy and spinal cord injury. Baclofen
and Tizanidine are the drugs of choice. Baclofen is the largest prescribed drug for this
indication, world wide.
In the market, Baclofen is available as conventional tablets, orally disintegrating tablets
and once-daily GRS tablets. The conventional and orally disintegrating tablets need to be
administered 3-4 times a day (for several days) leading to poor patient compliance and 
there is also increased incidence of  side effects with  these formulations. The patient
compliance can be improved and the side effects can be minimized with the once-daily
formulation. Even though once-daily extended release GRS is available in the market 
(Baclof OD, INTAS pharmaceuticals), it is very expensive as it is a coated multi-layer gas
generating floating tablet.
Rationale for Drug Selection[38]:
• Baclofen has a biological half-life of 2.5-4 hours. Hence, the conventional tablets
need to be administered 3-4 times a day (for several days) leading to poor patient 
compliance. Therefore, Baclofen is suitable candidate for the development of
once-daily formulation.
• Adverse events associated with Baclofen can be minimised when administered as 
once-daily formulation.
• Absorption of the Baclofen is limited to stomach or upper part of the GI tract i.e,
its absorption on arrival to colon (or even before) is low or nonexistent and 
therefore its bioavailability is incomplete when administered as a normal sustained 
release formulation. The bioavailability of the drug can be increased by making
the drug completely absorbed in the stomach by sustained release gastro-retentive
drug delivery system considering the fact that Baclofen is stable under gastric
condition.
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Preformulation Studies
• Determination of solubility of BCF in 0.1N HCl.
• To characterize the in-situ interactions between the drug and other excipients, if
any by FT-IR examination.
• Determination of pre-compression parameters of the powder blends of various 
formulations.
         Formulation
• To develop suitable formulae and procedure for the manufacture of BCF sustained
release floating tablets in a relatively economical way.
• To formulate BCF SR floating matrix tablets using polymers HPMC K4M
,HPMC K15M, HPMC K100M, Polyethylene oxide WSR-301, Polyethylene
oxide WSR-303 (synthetic polymers) and Xanthan, guar gum (natural polymers) 
and sodium  bicarbonate as the effervescent  agent  by direct  compression
technique.
Evaluation
• To evaluate the post-compression parameters of the prepared tablets.
• In-vitro evaluation of the gastro-retentive tablets for the buoyancy and drug
release characteristics.
• To analyze the rate and mechanism of release of Baclofen from the prepared
floating tablets and the marketed formulation.
• Selection of the optimized formulation.
• Comparison of the optimized formulation with the marketed product.
• Determination of similarity factor.
In view of these objectives, an extensive literature search was done and the important
aspects were highlighted in the chapter, “Literature Review”.
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Table 5.1: Materials used for the formulation development
S.No. Materials Source
1 Baclofen Gift sample from Natco pharma Ltd.,Hyderabad
2 HPMC K4M Colorcon Asia Pvt Ltd.,Goa
3 HPMC K15M Colorcon Asia Pvt Ltd.,Goa
4 HPMC K100M Colorcon Asia Pvt Ltd.,Goa
5 Xanthan gum Loba Chemie Pvt. Ltd., Mumbai
6 Guar gum Loba Chemie Pvt. Ltd., Mumbai
7 PEO WSR-301 Colorcon Asia Pvt Ltd.,Goa
8 PEO WSR-303 Colorcon Asia Pvt Ltd.,Goa
9 Sodium bicarbonate S.D. Fine chemicals Ltd., Mumbai
10 Avicel PH-102 Signet chemical corporation, Mumbai
11 Talc S.D. Fine chemicals Ltd., Mumbai
12 Magnesium stearate
S.D. Fine chemicals Ltd., Mumbai
13 Hydrochloric acid Loba Chemie Pvt. Ltd., Mumbai
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Table 5.2: Instruments and Equipment used for the investigation
S.No.
Name of the Instrument/ 
Equipment
Manufacturers name
1 Electronic weighing balance Dhona-200D
2 Micropipettes S.D. Fine chemicals Ltd., Mumbai
3
Double beam UV-VIS
spectrophotometer
Shimadzu UV-1800
4
Single beam UV-VIS 
Spectrophotometer
Elico SL-150
5 Rotary shaker Remi Rotary Shaker
6 FT-IR Spectrophotometer Perkin-Elmer, Spectrum 100 FTIR
7 Tablet compression machine Cadmach Machinery, Ahmedabad
8 PH meter Elico LI 120
9 Dissolution test apparatus eight stage LABINDIA, DS 8000
10 Monsanto Hardness tester
Campbell Electronics, model EIC-
66, India
11 Sonicator Loba Life
12 Roche Friabilator Campbell Electronics, Mumbai
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The following methodology was employed for the investigation:
5.1. PRE-FORMULATION STUDIES:
Pre-formulation may be described as a stage of development during which the 
physicochemical and biopharmaceutical properties of a drug substance are characterized. It
is an important part of the drug development process. The information relating to drug 
development  acquired during this phase is used for making critical decisions in 
subsequent stages of development. A wide variety of information must be generated to 
develop formulations rationally. Characterization of the drug is a very important step at 
the pre-formulation phase of product development followed by studying the properties of
the excipients and their compatibility.
Pre-formulation testing is the first step in the rational development of dosage forms. It
can be defined as an investigation of physical and chemical properties of a drug substance 
alone and when combined with excipients.
The objective of pre-formulation testing is to generate information useful to the 
formulator in developing stable and bioavailable dosage forms that can be mass produced.
The use of pre-formulation parameters maximizes the chances in formulating an 
acceptable, safe, efficacious and stable product and at the same time provides the basis for 
optimization of the drug product quality.
5.1.1. ORGANOLEPTIC EVALUATION:
Organoleptic characters like color, odor, and taste of drug were observed and recorded
using descriptive terminology.
5.1.2. DEVELOPMENT OF ANALYTICAL METHOD:
A survey of literature reveals that few analytical methods such as HPLC, UV/VIS
spectrophotometric methods were reported for the estimation of Baclofen in formulations.
A simple, economic, convenient, reproducible and precise UV spectrophotometric
method was employed for the assay as well as for the in-vitro dissolution studies.
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UV Spectroscopy:
Preparation of Stock solution:
50mg of the drug (BCF) was accurately weighed and transferred to the 50mL volumetric
flask. It was dissolved in sufficient quantity of 0.1N HCl and volume was made upto the
mark with 0.1N HCl to obtain a stock solution of 1000µg/mL.
Determination of UV Absorption Maxima (λmax) of Baclofen in 0.1N HCl :
From the stock solution, 50µ L was transferred to a 5mL volumetric flask and the volume
was made upto the mark with 0.1N HCl. The resulting solution containing 10µ g/mL BCF
in 0.1N HCl was scanned from 200-400 nm in 0.1N HCl as a blank using double beam
UV/VIS spectrophotometer. The wavelength maximum was found to be at 220 nm.
Construction of the calibration curve:
An accurately weighed quantity of BCF (50mg) was dissolved in 50mL of 0.1N HCl to
generate a stock solution having concentration of 1000µ g/mL. From the stock solution,
appropriate aliquots (10,20,30,40,50µL) were transferred to different volumetric flasks of
5ml capacity  and made upto the volume with 0.1N HCl to obtain solutions with 
concentrations 2,4,6,8,10µ g/mL respectively. The absorbance of the solutions were
measured at 220nm against blank (0.1N HCl) using UV-visible spectrophotometer. The 
procedure was performed in triplicate to validate the calibration curve.
The absorbance values relating to different concentrations of BCF are given in Table 6.1. 
The absorbance was plotted against concentration of BCF as shown in Fig. 6.1.
5.1.3.  DETERMINATION OF SOLUBILITY:
The following procedure was employed to determine the solubility of BCF in 0.1N HCl.
Excess of BCF was added to 5mL of 0.1N HCl in a 25mL stoppered conical flask and the
mixture was shaken for 24 hours at room temperature (28±1oC) on rotary shaker. After 24
hours of shaking 1mL aliquots were withdrawn at different time intervals and filtered
immediately using a 0.45µ nylon disc filter. The filtered samples were diluted suitably
and assayed for BCF by measuring the absorbance at 220nm. Shaking was continued until
three consecutive estimations were same. The results are given in Table 6.2.
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5.1.4. DRUG–EXCIPIENT COMPATIBILITY STUDY:
In the preparation of the tablets, drug and other excipients may interact as they are in
contact with each other, which could lead to the instability of dosage form. Pre-
formulation studies regarding the drug-excipient interaction are therefore very crucial in 
selecting appropriate excipients. FT-IR spectroscopy was employed to ascertain 
the compatibility between the drug and the  selected excipents. The drug alone and 
physical mixtures of drug with excipients (1:1 ratio) were scanned separately in the range
of 4000-500 cm-1 using KBr disc method.
Procedure: 1-2mg of the sample to be examined was triturated with 300-400 mg 
specified quantity of finely powered and dried potassium bromide. These quantities are 
usually sufficient to give a disc of 10-15mm diameter and pellet of suitable intensity by a 
hydraulic press. The Infrared spectrum was recorded by using FT-IR spectrophotometer
and observed for characteristic peaks of the drug.
5.1.5. DETERMINATION OF MICROMERITIC PROPERTIES OF THE 
POWDER BLENDS:
The following tests  were performed in-order to determine the flow properties of the
powder blends.
Bulk Density[49] :
Bulk density is of great importance when one considers the size of a high-dose drug
product or  homogeneity of a low-dose  formulation.  The homogeneity  of a low-dose 
formulation in which there are large  differences  in drug  and excipient could lead to
segregation.
Apparent Bulk density (g/mL) was determined by pouring (pre-sieved 18-mesh) gently
10g of the sample through a glass funnel into a 50mL graduated cylinder. Then after
pouring the powder bed was made uniform without disturbing. Then the volume was
measured directly from the graduation marks on the cylinder as mL. The volume measure
was called as the bulk volume and the bulk density was calculated by following formula.
Bulk density = Weight of powder / Bulk volume
PGPCOPS & RI.  NAMAKKAL. Page 34
MATERIALS AND METHODS
Tapped Density [49] :
Tapped density (g/mL) was determined by pouring gently 10g of sample through a glass
funnel into a 50mL graduated cylinder. The cylinder was tapped from height of 2 inches 
until a constant volume was obtained (100 taps).Volume occupied by the sample after
tapping was recorded as the tapped volume (mL) and tapped density was calculated from
the formula.
Tapped density = Weight of powder / Tapped volume
Carr’s Compressibility Index(%) [49]:
Compressibility is the ability of powder to decrease in volume under pressure. 
Compressibility is a measure that is obtained from density determinations. It is also one
of the simple methods to evaluate flow property of powder by comparing the bulk density 
and tapped density.
High density powders tend to possess free flowing properties. A useful empirical guide is
given by the Carr’s index or compressibility index calculated from bulk density and
tapped density.
Compressibility index = 1      
    
   100
Where,
V = volume of powder blend before tapping
V0 = volume of powder blend after 100 tappings
Hausner’s ratio[49]:
Hausner’s ratio provides an indication of the degree of densification which could result
from vibration of the feed hopper. A lower value indicates better flow and vice versa.
Hausner’s ratio = Tapped density /Bulk density
Angle of repose [49]:
The frictional force in a loose powder can be measured by the angle of repose. Angle of
repose (θ) is the maximum angle between the surface of a pile of powder and horizontal
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plane. It is usually determined by Fixed funnel method and is the measure of the 
flowability of powder/granules.
A funnel with 10mm inner diameter of  stem was fixed at a height of 2cm over the
platform. The sample was slowly passed along the wall of funnel, till the cone of the
powder formed. Angle of repose was determined by measuring the height of the cone of
powder and radius of the heap of the powder. Angle of repose was calculated using the
following formula
θ = ta 1 (h/r)
where,
θ = Angle of repose
h = Height of the powder cone
r = Radius of the powder cone
The specifications for flow characteristics of powders are given in Table 5.3.
Table 5.3: Specifications for flow characteristics of powders
S.NO
TYPE OF 
FLOW
ANGLE OF 
REPOSE(°)
COMPRESSIBILITY 
INDEX (%)
HAUSNER’S 
RATIO
1. Excellent 25-30 <10 1.00-1.11
2. Good 31-35 11-15 1.12-1.18
3.
Fair (aid not
needed)
36-40 16-20 1.19-1.25
4.
Passable 
(may hang 
up)
41-45 21-25 1.26-1.34
5.
Poor (must
agitate, 
vibrate)
46-55 26-31 1.35-1.45
6. Very poor 56-65 32-37 1.46-1.59
7.
Very very 
poor
>66 >38 >1.6
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5.2. FORMULATION OF BACLOFEN SR FLOATING MATRIX TABLETS: 
FORMULATION PLANNING:
Dose calculations involved in sustained drug delivery:
The amount of drug required in a sustained release dosage form, to provide a sustained
drug level in the body is determined by the pharmacokinetics of the drug, the desired
therapeutic level of the drug and the intended duration of action.
Pharmacokinetic parameters of Baclofen:
Elimination half life (t1/2) = 4 hrs
Time to reach peak plasma concentration (tp) = 3 hrs
Calculations involved in the preparation of BCF sustained release floating tablets:
Conventional dose of Baclofen was found to be 5mg. This was considered as Initial dose
(DI).
Calculation of elimination rate constant:
Elimination rate constant (Kel) =0.693/t1/2
=0.693/4
= 0.173/ hr
Calculation of zero order release rate constant:
Desired release rate from maintenance dose (k0) = DI x Kel
= 5 x 0.173
= 0.866 mg/hr
Calculation of maintenance dose:
Maintenance dose (DM) = DI x Kel x T  [T= Time over which sustained dose is released]
= 5 x 0.173 x 24
= 20.79 mg
Calculation involved in correcting the initial dose:
Corrected DI = DI – [tp x DI x Kel]
= 5-[3 x 5 x 0.173]
=2.40 mg
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Calculation of total dose:
Total dose = DM + corrected DI
=20.79 +2.40
=23.19 mg
From the above calculations total dose for the sustained release of Baclofen for 24 hrs is
23.19 mg. The total dose was rounded to 23 mg for the convenience.
Tablets containing 23 mg of BCF were prepared with a total tablet weight of 200 mg. 
Considering the Pre-formulation studies carried out, direct compression technique has
been  employed to produce cost effective sustained release floating matrix tablets  by 
effervescent approach.
Selection of polymers:
Hydrophilic swellable matrix polymers were selected as they were reported to have 
positive effect on floating behavior. Polymers are selected according to their drug 
retarding ability inorder to sustain the drug release for 24 hours. HPMC K4M, HPMC
K15M, HPMC K100M, PEO WSR-301, PEO WSR-303 (Synthetic polymers) and 
xanthan gum, guar gum (natural polymers) were selected for the present investigation.
Selection of Effervescent agent:
Sodium  bicarbonate (25-50%) is used  in pharmaceutical formulations  as a source of 
carbon dioxide in effervescent tablets and granules. When the tablet or granules come in
contact with gastric acid (0.1N HCl), a chemical reaction occurs, CO2 is evolved which 
gets entrapped in the swellable hydrophilic polymer matrix, which is responsible for the 
buoyancy of the formulation. Hence, sodium bicarbonate was selected as the effervescent
agent in the formulation.
Selection of diluents:
Since Direct compression technique was employed, the choice of directly compressible
diluents was important. Microcrystalline cellulose was selected as the filler or diluent
owing to its multiple functionality as binder, disintegrant, compressibility and flowability. 
Microcrystalline cellulose also acts as wicking agent, that promotes the influx of water 
into the system and thereby improves the floating lag time of the FDDS. Moreover, it was
proved[50] that microcrystalline cellulose is capable of swelling in contact with aqueous
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fluids as simulated gastric fluid leading to an increase in the  water uptake capacity,
porosity of the matrix and consequently would enhance floating abilities. Of the various 
grades available, Avicel PH-102 was selected as it had been already reported to provide
lower crushing strengths.
Selection of other ingredients:
To further improve the flow property of the blend, talc and magnesium stearate were used
as lubricant and glidant respectively.
Formulae of floating matrix tablets of BCF are given in Tables 5.4 and 5.5.
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Table 5.4: Formulae of floating matrix tablets of BCF:
Ingredients
(%w/w of 200 mg tablet)
F1 F2 F3 F4 F5 F6 F7 F8 F9
BCF 11.5 11.5 11.5 11.5 11.5 11.5 11.5 11.5 11.5
HPMC K100M 30 40 20 25 30 40 40 — —
HPMC K15M — — — — — — — 40 —
HPMC K4M — — — — — — — — 40
Sodium bicarbonate 25 25 10 10 10 10 12.5 12.5 12.5
Avicel PH -102 31.5 21.5 56.5 51.5 46.5 36.5 34 34 34
Talc 1 1 1 1 1 1 1 1 1
Magnesium stearate 1 1 1 1 1 1 1 1 1
Total 100 100 100 100 100 100 100 100 100
Table5.5: Formulae of floating matrix tablets of BCF:
Ingredients
(%w/w of 200 mg tablet)
F10 F11 F12 F13 F14
BCF 11.5 11.5 11.5 11.5 11.5
Guar gum 40 — — — —
Xanthan gum — 40 — — —
PEO WSR-301 — — 40 — —
PEO-301+HPMC K100M(4:1) — — — 40 —
PEO WSR-303 — — — — 40
Sodium bicarbonate 12.5 12.5 12.5 12.5 12.5
Avicel PH-102 34 34 34 34 34
Talc 1 1 1 1 1
Magnesium stearate 1 1 1 1 1
Total 100 100 100 100 100
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Procedure for the preparation of tablets:
BCF and all other ingredients were individually passed through sieve no≠60. Accurately 
weighed quantities of drug, polymer, sodium bicarbonate, MCC were transferred to a 
polythene bag and  mixed homogenously for 15 minutes. The powder mix was then 
lubricated with talc and magnesium stearate. The powder blend was compressed into
tablets on a single punch tablet machine using 8 mm flat round punches.
5.3. EVALUATION OF FLOATING TABLETS:
All the prepared tablets were evaluated for the following parameters:
5.3.1. Post-compression parameters: 
Hardness[51]:
The hardness of the tablets was measured with a Monsanto hardness tester. The results
reported were mean and standard deviation of 3 tablets for each formulation and
expressed in kg/cm2. Oral compressed tablets normally have a hardness of 4-9 kg/cm2.
Friability (%F) [51]:
20 tablets from each batch were selected randomly and weighed. These pre-weighed
tablets were subjected to friability testing using Roche friabilator for 100 revolutions. The 
tablets were subjected to the combined effect of abrasion and shock in a plastic chamber
revolving at 25 rpm and dropping a tablet at height of 6 inches in each revolution. Tablets 
were removed, de-dusted and weighed again. Following formula was used to calculate the
%friability
%F = 1 – (Final weight / Initial weight ) 100
A maximum weight loss of not more than 1% of the tablet weight during the friability test
is generally considered acceptable.
Weight variation[51]:
20 tablets were randomly selected from each batch, weighed individually. The average
weight and standard deviation of 20 tablets was calculated. The batch passes the test if the 
weights of not more than 2 of tablets differ by more than the percentage listed in Table
5.6 and no tablets differ in weight by more than double that percentage.
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Table 5.6: Weight variation allowed for uncoated tablets
Average weight of tablet (mg) Percentage difference allowed
≤ 130 10
130-324 7.5
>324 5
Drug content uniformity[51]:
Five tablets were weighed individually, then placed in a mortar and powdered with a 
pestle. Accurately weighed powder sample (200mg) equivalent to 23mg  of BCF was
transferred to a 100mL volumetric flask, and made upto volume 0.1N HCl. The contents
of the volumetric flask were sonicated for 15 minutes inorder to extract the drug into 0.1N 
HCl. The solution was then filtered, suitably diluted with 0.1N HCl and the absorbance
was measured at 220nm.The estimations were carried out in triplicate and the results are
given in Table 6.4.
5.3.2. In-vitro buoyancy study [43]:
The study involves the determination of the floating lag time and total floating time.
Floating lag time is the time required for the tablet to emerge onto the surface of the
dissolution medium from the bottom of the dissolution vessel. The duration of floating
(total floating time) is the time the dosage form constantly floats on the surface of the
dissolution medium (excluding floating lag time).
Procedure: 3 tablets from each batch were transferred to USP XXI type- II dissolution 
apparatus containing 900 mL  of 0.1N HCl. The study was performed at the  paddle
rotational speed of 50 rpm and temperature of 37±0.5°C.The floating lag time and the
total floating time were recorded by visual observation using a stop watch. The results are
given in Table 6.5.
5.3.3. In-vitro drug release study [43]:
The tablet samples were subjected to in-vitro dissolution study using USP XXI type II 
(Paddle method) Dissolution rate test apparatus at a temperature of 37+0.5°C and 50 rpm 
speed. 900 mL of 0.1N HCl (pH-1.2) was used as the dissolution medium. Aliquot equal
to 5mL was withdrawn at specific time intervals for 24 hours. The dissolution media
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volume was complimented with fresh and equal volume of blank media (0.1N HCl). The
aliquots were filtered and assayed for BCF by measuring the absorbance at 220 nm
against blank (0.1N HCl). The dissolution experiments were carried out in triplicate. The
results are given in Tables 6.6-6.20.
Table 5.7: Dissolution parameters
Apparatus used
USP XXI tablet
dissolution test apparatus-
II
Dissolution medium 0.1N HCl (pH- 1.2)
Dissolution medium 
volume
900 mL
Temperature 37±0.5ºC
Paddle speed 50 rpm
Sample volume withdrawn 5 mL
Sampling intervals (hrs)
0.5,1,2,3,4,6,8,10,12,16,24
.
Absorbance measured at 220 nm
5.4. MATHEMATICAL MODEL FITTING OF OBTAINED DRUG RELEASE
DATA:
The rate and mechanism of release of BCF from the prepared tablets were analysed by
fitting the dissolution data into
Zero order kinetics
First order kinetics
Higuchi model
Korsmeyer –Peppas model
5.4.1 Zero order kinetics[52]:
This equation describes the systems where the release rate is independent of the 
concentration of the dissolving species. The equation describing the kinetics is given
below
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Qt= Qo + Ko t
Where
Qt = amount of drug dissolved in time t
Qo = initial amount of drug in the solution
Ko = zero order release constant
For zero order release kinetics, the graph was plotted between cumulative percent of drug
released versus time.
Dosage forms following this profile, release same amount of drug per unit time, and it is
the ideal method of release for a sustained release product.
5.4.2. First order kinetics[53]:
Gibaldi and Feldman first proposed the application of this model to drug dissolution 
studies in 1967. The First order equation describes the release from systems where the 
release rate is dependent upon the concentration of the dissolving species. The equation
is given below:
.    
Where, Co is the initial concentration of the drug, K is the first order rate constant, and t
is the time. The data obtained are plotted as log cumulative % of drug remaining Vs time
which would yield a straight line with a slope of –K/2.303.
For first order release kinetics, the graph was plotted between log cumulative percent of 
drug remaining versus time.
5.4.3. Higuchi model[54]:
Higuchi first proposed this model to describe dissolution of drug in suspension from
ointment bases, but is widely applicable to other types of dosage forms. The equation is
given below:
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Where Q is the amount of drug released at time t per unit area A, C is the initial drug 
concentration, Cs is the drug solubility in the matrix media and D is the diffusivity of the
drug molecules in the matrix substance.
Simplified Higuchi model
Ft = KH × t
1/2
Where KH is the Higuchi dissolution constant. For Higuchi model, the graph was plotted 
between cumulative percent of drug released versus square root of time. The linearity of 
the graph indicates the diffusion controlled release.
5.4.4. Korsmeyer –Peppas model[55]:
Korsmeyer and Peppas, in 1983 derived a mathematical equation which described the 
mechanism of drug release from a polymeric system. It is also known as Power law which 
is more comprehensive in describing the drug release mechanism as compared to Higuchi 
model. To find out the mechanism of drug release, first 60% drug release data were fitted
in Korsmeyer –Peppas model
Mt/M∞ =K t
n
Where Mt/M∞ is a fraction of drug released at time t, K is the release rate constant and ‘n’ 
is the release exponent. For Korsmeyer-Peppas model, the graph was plotted between log 
cumulative percent of drug released versus log time. From the graph, the value of ‘n’
characterizes the release mechanism of drug as described in Table.5.8.
Table 5.8: Interpretation of drug release mechanism from drug release data
(Peppas, 1983).
Exponent, ‘n’
Drug release MechanismThin film Cylinder Sphere
0.5 0.45 0.43 Fickian Diffusion
0.5<n<1.0 0.45<n<0.85 0.43<n<0.85
Non – Fickian Diffusion/Anomalous
Transport
1.0 0.89 0.85 Zero order/ Case II transport
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When the exponent ‘n’ takes a value of 1.0, the drug release rate is independent of time. 
This case corresponds to zero-order release kinetics (also termed as case II transport). 
Here the relaxation process of the macromolecules occurring upon water imbibitions into
the system is the rate-controlling step. When n = 0.5, Fickian diffusion is the drug release 
mechanism. Thus, Equation has two distinct physical meanings in the two special cases of
n=0.5 (indicating  diffusion-controlled  drug release) and n=1 (indicating swelling-
controlled drug release).  Values of n between 0.5 and 1.0 can be regarded as an indicator 
for the superposition of both phenomena (anomalous transport).  It has to be kept in mind 
that the two extreme values for the exponent ‘n’ 0.5 and 1.0 are only valid for slab
geometry.
5.5. OPTIMIZATION OF TABLET FORMULATION:
Based upon the buoyancy characteristics and percent cumulative drug release, the 
optimised formulation was selected.
5.6. RELEASE PROFILE COMPARISON:
The release profile of the optimized formulation was compared with the release profile of 
the marketed formulation.
Determination of Similarity factor, f2 value
[56]:
This factor was introduced by Moore and Flanner and has been adopted by the centre for 
Drug Evaluation and Research (US FDA) and by Human Medicines Evaluation Unit of 
the European Agency for the Evaluation of Medicinal Products (EMEA) as a criterion for 
the assessment of the similarity between two dissolution profiles. It is included in various 
guidance documents. The similarity factor f2   as defined by FDA and EMEA is a 
logarithmic reciprocal square root transformation of one plus the mean squared (the 
average sum of squares) differences of percent drug dissolved between the test and
reference products:
  /   
.! 100$
Where, n is the number of dissolution time points.
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Rt and Tt are the reference and test dissolution values (mean of at least 12 dosage units)
at time t.
FDA recognizes the release profiles to be similar when the f2 value is between 50 and
100.
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RESULTS AND DISCUSSION
Spasticity, a condition in which certain muscles are continuously contracted, affects over
12 million worldwide. Generally, spasticity is associated with common neurological 
disorders like multiple sclerosis, stroke, cerebral palsy and spinal cord injury. Baclofen is
the largest prescribed drug for this indication, world wide.
The half-life of  the drug  is ~2.5 to 4 hrs in plasma which requires frequent dosing 
(conventional tablets). The patient compliance can be improved and the side effects can
be minimized with the once-daily formulation.
Baclofen is difficult to formulate into sustained release dosage forms because it has an 
absorption window in upper G.I. tract and on arrival to colon (or even before) its
absorption is diminished or nonexistent resulting in low bioavailability. Hence, in the
present investigation, efforts were made to increase the residence time of Baclofen at the 
absorption window by formulating sustained release gastro-retentive floating tablets
inorder to improve the bioavailability considering the fact that Baclofen is stable under
gastric condition.
The results of the investigation are summarized as follows:
6.1. PREFORMULATION STUDIES:
6.1.1. Organoleptic evaluation:
Baclofen is a white crystalline powder, virtually odorless, with slightly bitter taste.
6.1.2. Analytical method:
Determination of UV Absorption Maxima (λmax) of Baclofen in 0.1N HCl :
A 10 µ g/mL solution of Baclofen in 0.1N HCl was scanned from 200-400 nm using
double beam UV/VIS Spectrophotometer. The wavelength maximum was found to be
220 nm as shown in Fig.6.
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220 nm
Fig 6: Scanning graph of BCF in 0.1N HCl
Standard calibration curve of Baclofen in 0.1N HCl (pH-1.2):
The dissolution medium employed for the gastro-retentive tablets is 0.1N HCl (pH-1.2) 
(Simulated gastric fluid). Hence, the calibration curve of BCF was constructed in 0.1N
HCl.
2,4,6,8,10 µ g/mL solutions of Baclofen in 0.1N HCl were prepared and the absorbance
values relating to different concentrations of BCF were measured at 220nm against blank 
(0.1N HCl) using UV/VIS spectrophotometer. The absorbance values relating to different 
concentrations of BCF are given in Table 6.1. The absorbance was plotted against
concentration of BCF as shown in Fig. 6.1.
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Table 6.1: Calibration curve data for the estimation of BCF in 0.1N HCl
Concentration (µg/mL)
ABSORBANCE(nm)
Trial -I Trial -II Trial -III Mean± S.D
2 0.061 0.063 0.05 0.058±0.007
4 0.098 0.106 0.098 0.101±0.005
6 0.155 0.167 0.154 0.159±0.007
8 0.203 0.228 0.195 0.209±0.017
10 0.261 0.279 0.253 0.264±0.013
0.30
0.25 y = 0.026x + 0.002
R² = 0.998
0.20
0.15
0.10
0.05
0.00
0 2 4 6 8 10 12
CONC(µg/mL)
Fig 6.1: Standard calibration curve of BCF in 0.1N HCl
The present analytical method obeyed Beer-Lambert’s law in the concentration range of
2-10 µg/mL. The R2 (correlation coefficient) value for the linear regression equation was
found to be 0.998. The linear regression equation was found to be
y=0.026x+0.002
The selected method was found to be sensitive, accurate, precise and reproducible and
used for the estimation of Baclofen in the present investigation.
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6.1.3. Solubility study:
The dissolution medium employed for the gastro-retentive tablets is 0.1N HCl (pH-1.2) 
(Simulated gastric fluid). Hence, the solubility of Baclofen in 0.1N HCl was determined 
inorder to verify whether sink condition can be maintained in the in-vitro dissolution
process employing 0.1N HCl as the dissolution medium. The results of the solubility
study are reported in Table 6.2.
Table 6.2: Solubility determination of BCF in 0.1N HCl
MEDIUM
ABSORBANCE 
(nm)
DILUTION 
FACTOR
SOLUBILITY 
(mg/mL)
0.1N HCl 0.657 1000 25.2
Practically, the solubility of Baclofen in 0.1 N HCl (Simulated gastric fluid) was found to 
be 25.2 mg/mL.
From the solubility study, it was evident that the sink condition can be maintained in the 
in-vitro dissolution process employing 0.1N HCl as the dissolution medium.
6.1.4. Drug- excipient compatibility study:
FT-IR interpretation[40]:
FT-Infrared spectroscopy was employed to find out the compatibility of drug with the
excipients. This study was carried out to find out the possible interaction between the
selected drug BCF and the excipients.  FT-IR spectrum  of  Baclofen  showed  the
following characteristic peaks at 1093cm-1 (due to –C-Cl), 1526 cm-1 (due to -COOH),
and 1626 cm-1 (due to –NH2). These prominent peaks of drug were also present in the IR
spectra of physical mixtures of drug with various excipients, thus revealing compatibility 
of the selected drug with the excipients. The FT-IR spectra are shown in Figs. 6.2-6.13.
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Fig 6.2: FT-IR spectrum of BCF
Fig 6.3: FT-IR spectrum of BCF-HPMC K100M
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Fig 6.4: FT-IR spectrum of BCF-HPMC K4M
Fig 6.5: FT-IR spectrum of BCF-HPMC K15M
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Fig 6.6: FT-IR spectrum of BCF-PEO WSR-301
Fig 6.7: FT-IR spectrum of BCF-PEO WSR-303
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Fig 6.8: FT-IR spectrum of BCF- Xanthan gum
Fig 6.9: FT-IR spectrum of BCF- Guar gum
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Fig 6.10: FT-IR spectrum of BCF-Sodium bicarbonate
Fig 6.11: FT-IR spectrum of BCF-MCC
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Fig 6.12: FT-IR spectrum of BCF-Talc
Fig 6.13: FT-IR spectrum of BCF-Magnesium stearate
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6.1.5. Determination of micromeritic properties of powder blends:
The powder blends of the formulations were evaluated for micromeritic properties like bulk 
density, tapped density, Carr’s compressibility index and Hausner’s ratio. The results are 
reported in Table 6.3.
Table 6.3: Micromeritic properties of powder blends of various formulations
Batch 
code
Angle of 
repose(θ)
Bulk
Density(g/mL)
Tapped 
density(g/mL)
Carr’s 
index(%)
Hausner’s 
ratio
F1 34.90° 0.222 0.256 13.28 1.15
F2 32.34° 0.266 0.310 14.19 1.17
F3 34.54° 0.258 0.291 11.30 1.13
F4 33.18° 0.281 0.321 12.46 1.14
F5 32.77° 0.242 0.279 13.26 1.15
F6 31.32° 0.240 0.280 14.28 1.17
F7 32.54° 0.250 0.290 13.79 1.16
F8 33.30° 0.298 0.345 13.62 1.15
F9 32.80° 0.266 0.309 13.91 1.16
F10 33.04° 0.311 0.355 12.39 1.14
F11 34.18° 0.240 0.270 11.11 1.13
F12 33.43° 0.296 0.342 13.45 1.16
F13 34.23° 0.311 0.356 12.64 1.14
F14 32.31° 0.250 0.287 12.89 1.15
Bulk density:
The bulk density of the powder blends ranged between 0.222-0.311 g/mL.
Tapped density:
The tapped density of the powder blends ranged between 0.256-0.356 g/mL.
Carr’s compressibility index:
If the compressibility index of the powder blend ranged between 11-15 %, it indicates 
good flow property. All the blends were within the range (11.11-14.28%), indicating that
the blends exhibit good flow property.
Hausner’s ratio:
The Hausner’s ratio of the powder blends ranged between 1.13-1.17. It indicates good
flow property of the blends.
Angle of repose(θ) :
The angle of repose for all the powder blends ranged between 31.32°-34.90°, indicating
good flow property of the blends.
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From the results, the powder blends of all the formulations were found to possess good
flow property. Hence, direct compression technique was employed for the preparation of
BCF tablets.
6.2. EVALUATION OF BCF FLOATING TABLETS:
The floating tablets of BCF were prepared by direct compression technique using 
effervescent approach.
All the prepared tablets were evaluated for the following parameters:
6.2.1. Post-compression parameters:
The formulated tablets were evaluated for various physico-chemical parameters like 
hardness, weight variation, friability, drug content uniformity. The results are reported as 
mean ± S.D. The results are reported in Table 6.4.
Table 6.4: Post-compression parameters of BCF floating tablets
Formulations
Avg. wt(mg)
Mean ± S.D
Hardness
(kg/cm2)
Friability
(% wt. loss)
Drug 
Content 
(%)
F1 197±1.3 6.83±0.29 0.46 96.11±0.76
F2 197±1.8 7.0±0.5 0.29 95.89±0.42
F3 198±2.5 4.17±0.29 0.51 98.47±0.83
F4 199±1.2 4.33±0.29 0.21 97.0±0.34
F5 197±1.6 4.17±0.29 0.41 97.12±0.36
F6 196±1.4 4.17±0.29 0.57 101.4±0.52
F7 199±1.7 4.5±0.5 0.64 99.0±0.40
F8 197±2.2 4.0±0.00 0.57 98.39±0.66
F9 198±2.6 4.17±0.29 0.42 96.86±0.37
F10 201±1.9 4.33±0.29 0.36 98.64±0.21
F11 197±1.2 4.5±0.5 0.52 97.89±0.48
F12 197±2.9 4.33±0.29 0.45 96.5±2.22
F13 198±1.3 4.17±0.29 0.80 95.53±1.39
F14 199±0.7 4.5±0.00 0.43 97.09±1.59
Hardness:
Oral compressed tablets normally have a hardness of 4-9 kg/cm2. The hardness of the 
formulations ranged between 4.0- 7.0 kg/cm2. No significant difference in hardness values
of all batches of tablets prepared was observed. So, all formulations pass the test.
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Weight variation test:
Twenty tablets of each formulation were selected randomly and weighed individually 
using an electronic balance to check the weight variation as per USP. Not more than two
tablets should cross the preferred deviation. The acceptable deviation is 7.5%. All the
formulated tablets were within 7.5% deviation. So, all tablets pass the test.
Friability:
The test was performed to evaluate the ability of the tablets to withstand abrasion during 
packing, handling and transporting. A maximum weight loss of not more than 1% of the
tablet weight during the friability test is generally considered acceptable. The weight loss 
of all the tablets was within the limit (0.21%-0.80%). The percentage loss in weight of the 
formulations was reported in table.6.4.
Drug content uniformity:
This test is highly essential for determining the actual amount of drug present in the
tablets. For the drugs in tablet form, the official potency range that is permitted is not less
than 95% and not more than 105% of the labeled amount. From the results, the
percentage of BCF in all the formulations ranged from 95.53±1.39% – 101.4±0.52%. So,
all the tablet formulations were found to possess the claimed amount of the drug.
6.2.2. In-vitro Buoyancy study:
The study was performed using USP XXI type-II (paddle) dissolution apparatus 
containing 900mL of 0.1N HCl as the dissolution medium. The study was performed at 
the paddle rotational speed of 50 rpm and a temperature of 37±0.5°C.The floating lag
time and the total floating time were recorded by visual observation using a stop watch.
The results are reported in Table 6.5 and represented as bar graphs (Figs. 6.14-6.15).
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Table 6.5: Buoyancy determinations of BCF floating tablets
FORMULATIONS
PARAMETERS
FLT( SECONDS) TFT(HOURS)
F1 73.33±15.28 24
F2 210.67±21.01 24
F3 14.67±1.16 24
F4 20±2 24
F5 51±13.12 24
F6 160±26 24
F7 25.67±3.77 24
F8 28.33±1.53 24
F9 584±14.42 24
F10 458±8.19 24
F11 20.33±6.03 24
F12 31.67±10.02 12
F13 41±3.61 12
F14 53.33±9.45 14
F.M 63.67±4.01 24
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Fig 6.14: Floating lag time of the Formulations
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Fig 6.15: Total floating time of the Formulations
All the tablets were prepared by effervescent approach. Sodium bicarbonate was added as
the gas-generating agent. Sodium bicarbonate induced carbon dioxide generation in the 
presence of dissolution medium (0.1N Hydrochloric acid).
It was observed that the gas generated is trapped and protected within the gel, formed by
hydration of polymer thus decreasing the density of the tablet below 1 and tablet becomes
buoyant.
The duration of buoyancy of all the formulations (including marketed product) was found
to be 24h except for the formulations (F12,F13,F14) which were formulated using
different grades  of PEO. The reason for the less duration of buoyancy of these
formulations may be due to the failure of the polymer in maintaining the matrix integrity 
throughout the dissolution process. Hence, these formulations were rejected.
The buoyancy lag time of all the formulations (including marketed product) ranged 
between  14.67±1.16 – 584±14.42 seconds. Formulation F3 prepared using HPMC 
K100M-20%   and  sodium bicarbonate-10%  exhibited very less  floating lag time 
(14.67±1.16 seconds) and formulation F9 prepared using HPMC K4M-40% and sodium
bicarbonate 12.5%, exhibited very high floating lag time (584±14.42seconds).
Formulations F1-F7 were prepared using  polymer  HPMC  K100M.The  initial 
formulations F1 and F2 were formulated using sodium bicarbonate-25% with a hardness
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of 7 kg/cm2. The formulations exhibited higher lag times of 73.33±15.28 seconds and
210.67±21.01 seconds respectively. This may be due to the greater hardness of the 
tablets, which prevents the quick entry of the dissolution medium into the matrix which is
responsible for the acid-base reaction and thereby buoyancy.
Hence, the further formulations were formulated with a hardness of 4 kg/cm2. Formulations 
F3-F6  were formulated using sodium bicarbonate-10% and different
concentrations of the polymer (HPMC K100M). It was observed that, with the increase in
the polymer concentration, the floating lag time increased gradually. The increase in 
polymer concentration would possibly prevent the entry of media into the tablet matrix
and prolong the floating lag time. The influence of polymer concentration on the floating
lag time was clearly evident from the Fig. 6.16.
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Fig 6.16: Effect of polymer concentration on the Floating lag time
The floating lag time of formulation F6 was found to be 160±26 seconds. Hence, in order 
to further decrease the floating lag time, for formulation F7 the amount of sodium 
bicarbonate was increased to 12.5%.
Formulation F7 exhibited optimum floating lag time of 25.67±3.77 seconds. Hence, the 
optimum amount of sodium bicarbonate was fixed to be 12.5%, which was used in rest of
the formulations (F8-F14).
With formulations containing the same amount of polymer of the same grade (F6,F7),
floating lag time decreased with increase in concentration of sodium bicarbonate. This
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finding also supported by study of Baumgartner et al.[57] who reported that incorporation
of sodium bicarbonate in the matrix system helps to improve floating properties by 
reacting with gastric fluid when dosage form comes in contact with media.
With formulations containing the same amount of polymer of the same grade (F2,F6),
floating lag time decreased with decrease in the hardness of the tablets. Formulation F2 
with sodium bicarbonate-25% (hardness-7 kg/cm2) exhibited higher lag time than the
formulation F6  with sodium bicarbonate-10% (hardness-4 kg/cm2).Even though more
amount of sodium bicarbonate was used in formulation F2, the FLT was high. From the
finding, it can be concluded that hardness of the tablet is crucial for achieving optimal
buoyancy lag time.
Formulations F9 and F10 containing HPMC K4M and Guar gum respectively exhibited
very high lag times. The reason may be due to the inadequate gel strength of the HPMC 
K4M (escape of the CO2 gas at the initial stage from the weak gel layer) and F10 with
guar gum exhibited high lag time due to the erosion of the matrix at the initial stage of
dissolution(there is no quick formation of gel layer for the entrapment CO2 gas).
Formulation F11 prepared using xanthan gum-40% and sodium bicarbonate-12.5% 
exhibited floating lag time of 20.33±6.03 seconds and total floating time of 24 hours. The
marketed formulation (F.M) exhibited floating lag time of 63.67±4.01 seconds and total 
floating time of 24 hours.
From the Buoyancy study, it can be concluded that optimum amount of sodium 
bicarbonate and polymer with sufficient gel strength are essential to achieve optimum in-
vitro buoyancy.
6.2.3. In-vitro drug release study:
All the formulations (F1-F14) and the marketed formulation were subjected to in-vitro 
dissolution testing.
In-vitro dissolution study was carried out for all the batches of matrix tablets using 
USP XXI type-II (paddle type) dissolution apparatus at temperature 37 + 0.5°C and 50
rpm speed. 900 mL of 0.1N HCl was used as the dissolution medium. The drug release
data is given in Tables 6.6-6.20 and the dissolution profiles of the formulations are shown
in Figs. 6.17-6.31.
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Table 6.6: Mean ± S.D percent of BCF released from BCF floating tablets (F1)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 24.09 24.68 23.65 24.14±0.52
1 29.29 30.18 28.70 29.39±0.74
2 37.57 38.75 37.13 37.82±0.84
3 44.08 45.41 43.19 44.23±1.12
4 52.22 52.81 51.92 52.32±0.45
6 59.91 60.95 59.47 60.11±0.76
8 69.82 70.26 68.19 69.43±1.09
10 74.71 75.89 76.04 75.55±0.73
12 83.28 84.17 82.99 83.48±0.62
16 93.93 94.97 95.41 94.77±0.76
24 --- --- --- ---
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Fig 6.17: In-vitro dissolution profile of BCF from F1
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Table 6.7: Mean ± S.D percent of BCF released from BCF floating tablets (F2)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 18.18 17.44 18.47 18.03±0.53
1 26.77 25.73 27.36 26.62±0.82
2 34.61 33.87 35.20 34.56±0.67
3 43.63 43.04 41.86 42.85±0.90
4 49.26 48.37 50.29 49.31±0.96
6 57.54 56.65 57.99 57.39±0.68
8 61.10 61.98 60.95 61.34±0.56
10 69.08 68.34 69.67 69.03±0.67
12 74.12 74.26 74.71 74.36±0.31
16 83.14 83.58 84.47 83.73±0.68
24 96.45 95.41 96.01 95.96±0.52
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Fig 6.18: In-vitro dissolution profile of BCF from F2
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Table 6.8: Mean ± S.D percent of BCF released from BCF floating tablets (F3)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 29.82 31.03 29.55 30.13±0.79
1 39.97 41.32 41.32 40.87±0.78
2 54.29 51.19 52.40 52.62±1.56
3 59.16 58.35 59.97 59.16±0.81
4 63.62 65.51 66.32 65.15±1.39
6 77.66 78.87 81.84 79.46±2.15
8 92.51 93.19 90.36 92.02±1.48
10 99.41 99.01 99.68 99.37±0.34
12 --- --- --- ---
16 --- --- --- ---
24 --- --- --- ---
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Fig 6.19: In-vitro dissolution profile of BCF from F3
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Table 6.9: Mean ± S.D percent of BCF released from BCF floating tablets (F4)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 28.74 28.20 29.55 28.83±0.68
1 36.60 38.76 38.22 37.86±1.12
2 42.95 44.98 44.44 44.12±1.05
3 49.43 50.51 50.78 50.24±0.72
4 55.92 56.73 57.13 56.59±0.62
6 71.58 68.47 70.36 70.14±1.56
8 80.90 81.04 81.98 81.31±0.59
10 86.99 88.20 89.15 88.11±1.08
12 95.63 96.57 97.39 96.53±0.88
16 --- --- --- ---
24 --- --- --- ---
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Fig 6.20: In-vitro dissolution profile of BCF from F4
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Table 6.10: Mean ± S.D percent of BCF released from BCF floating tablets (F5)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 24.83 25.50 24.29 24.87±0.61
1 35.65 33.09 34.57 34.44±1.29
2 44.84 47.13 43.76 45.24±1.72
3 54.43 53.08 53.89 53.80±0.68
4 59.84 58.35 58.89 59.03±0.75
6 69.96 70.23 68.61 69.60±0.87
8 83.47 79.82 80.09 81.13±2.03
10 89.55 90.49 91.30 90.45±0.88
12 93.47 95.50 94.69 94.55±1.02
16 96.58 97.66 98.20 97.48±0.83
24 --- --- --- ---
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Fig 6.21: In-vitro dissolution profile of BCF from F5
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Table 6.11: Mean ± S.D percent of BCF released from BCF floating tablets (F6)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 22.26 19.30 21.86 21.14±1.61
1 31.87 28.49 31.46 30.61±1.84
2 38.09 34.71 38.36 37.05±2.03
3 49.29 45.92 48.89 48.03±1.84
4 52.54 48.76 52.81 51.37±2.27
6 59.43 54.30 59.29 57.67±2.92
8 67.94 61.32 66.45 65.24±3.47
10 77.39 73.20 80.49 77.03±3.66
12 85.09 79.02 86.99 83.70±4.16
16 94.01 88.33 96.03 92.79±3.99
24 101.03 95.50 100.09 98.87±2.96
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Fig 6.22: In-vitro dissolution profile of BCF from F6
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Table 6.12: Mean ± S.D percent of BCF released from BCF floating tablets (F7)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 20.51 21.99 21.18 21.23±0.74
1 37.13 34.30 37.00 36.14±1.60
2 42.54 40.92 44.16 42.54±1.62
3 47.95 46.60 49.03 47.86±1.22
4 51.87 50.38 53.22 51.82±1.42
6 64.29 61.45 64.69 63.48±1.77
8 66.73 64.16 67.94 66.28±1.93
10 76.58 74.82 77.12 76.18±1.20
12 83.34 80.50 84.15 82.66±1.91
16 95.76 91.44 95.22 94.14±2.35
24 100.77 98.20 98.74 99.23±1.35
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Fig 6.23:  In-vitro dissolution profile of BCF from F7
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Table 6.13: Mean ± S.D percent of BCF released from BCF floating tablets (F8)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 19.70 17.27 18.49 18.49±1.21
1 30.52 27.41 32.00 29.98±2.34
2 41.32 36.87 40.65 39.61±2.40
3 47.14 42.27 49.97 46.46±3.89
4 52.41 48.76 53.22 51.46±2.38
6 72.11 66.04 71.17 69.77±3.27
8 83.47 79.95 83.74 82.39±2.11
10 89.82 89.01 92.52 90.45±1.84
12 97.25 93.74 97.79 96.26±2.20
16 100.36 97.26 101.58 99.73±2.23
24 --- --- --- ---
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Fig 6.24: In-vitro dissolution profile of BCF from F8
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Table 6.14: Mean ± S.D percent of BCF released from BCF floating tablets (F9)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 23.21 21.72 22.40 22.44±0.74
1 33.08 32.41 32.68 32.72±0.34
2 38.90 41.87 42.41 41.06±1.89
3 49.56 50.24 51.05 50.29±0.75
4 56.19 53.08 55.24 54.84±1.59
6 75.22 71.17 74.00 73.46±2.08
8 86.71 84.28 86.44 85.81±1.33
10 95.90 94.95 96.44 95.76±0.75
12 --- --- --- ---
16 --- --- --- ---
24 --- --- --- ---
120
100
80
60
40
20
0
0 4 8 12 16 20 24
Time (hrs)
Fig 6.25: In-vitro dissolution profile of BCF from F9
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Table 6.15: Mean ± S.D percent of BCF released from BCF floating tablets (F10)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 31.17 31.44 31.98 31.53±0.41
1 39.97 41.46 40.92 40.78±0.75
2 50.10 49.43 49.70 49.75±0.34
3 56.46 56.46 56.05 56.32±0.23
4 61.59 60.78 60.92 61.10±0.43
6 73.34 73.61 72.93 73.29±0.34
8 80.64 82.26 81.72 81.54±0.82
10 89.95 90.77 90.23 90.32±0.41
12 93.74 94.42 93.88 94.01±0.36
16 95.77 97.66 96.31 96.58±0.97
24 96.72 100.63 98.74 98.70±1.96
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Fig 6.26: In-vitro dissolution profile of BCF from F10
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Table 6.16: Mean ± S.D percent of BCF released from BCF floating tablets (F11)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 12.14 11.87 10.53 11.51±0.87
1 17.15 16.34 17.28 16.92±0.51
2 23.50 23.09 23.77 23.45±0.34
3 36.32 30.66 31.60 32.86±3.04
4 43.62 38.22 41.32 41.06±2.71
6 61.31 56.58 57.26 58.38±2.56
8 76.17 67.12 70.63 71.31±4.56
10 84.82 80.22 80.23 81.76±2.65
12 88.88 86.45 87.39 87.57±1.23
16 92.39 91.45 91.85 91.90±0.48
24 98.74 97.66 99.01 98.47±0.71
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Fig 6.27: In-vitro dissolution profile of BCF from F11
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Table 6.17: Mean ± S.D percent of BCF released from BCF floating tablets (F12)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 14.30 14.03 13.76 14.03±0.27
1 21.07 18.50 19.18 19.58±1.33
2 30.79 27.28 27.14 28.40±2.07
3 39.84 37.27 38.35 38.49±1.29
4 48.89 45.38 47.81 47.36±1.80
6 66.17 61.44 65.77 64.46±2.62
8 83.46 78.33 83.87 81.89±3.09
10 91.85 87.93 91.98 90.59±2.30
12 93.61 91.58 93.88 93.02±1.26
16 --- --- --- ---
24 --- --- --- ---
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Fig 6.28: In-vitro dissolution profile of BCF from F12
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Table 6.18: Mean ± S.D percent of BCF released from BCF floating tablets (F13)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 13.09 10.25 11.47 11.60±1.42
1 16.21 13.77 18.36 16.11±2.30
2 24.98 23.22 27.82 25.34±2.32
3 34.84 33.89 39.70 36.15±3.12
4 43.89 42.68 47.27 44.61±2.38
6 62.12 60.23 63.34 61.89±1.57
8 77.52 75.22 78.47 77.07±1.67
10 83.61 81.72 85.23 83.52±1.76
12 85.51 85.10 89.69 86.76±2.54
16 87.53 87.53 91.18 88.75±2.11
24 --- --- --- ---
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Fig 6.29: In-vitro dissolution profile of BCF from F13
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Table 6.19: Mean ± S.D percent of BCF released from BCF floating tablets (F14)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 19.97 21.72 23.21 21.63±1.62
1 23.77 24.18 25.53 24.49±0.92
2 34.97 36.86 36.86 36.23±1.09
3 39.84 45.24 40.12 41.73±3.04
4 49.56 53.21 49.43 50.74±2.15
6 66.98 69.68 66.17 67.61±1.84
8 79.95 80.09 79.14 79.73±0.51
10 85.64 87.12 85.50 86.09±0.90
12 86.45 88.34 88.34 87.71±1.09
16 89.83 90.37 90.50 90.23±0.36
24 95.50 97.66 96.44 96.53±1.08
120
100
80
60
40
20
0
0 4 8 12 16 20 24 28
Time (hrs)
Fig 6.30: In-vitro dissolution profile of BCF from F14
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Table 6.20: Mean ± S.D percent of BCF released from Marketed formulation
(F.M)
Time(hrs)
% BCF released
Mean± SD
1 2 3
0 0 0 0 0
0.5 20.02 21.41 20.02 20.48±0.81
1 23.92 24.23 24.85 24.33±0.47
2 34.16 35.41 33.39 34.32±1.02
3 46.12 46.28 47.36 46.59±0.68
4 57.00 55.91 54.05 55.66±1.49
6 61.36 62.29 62.44 62.03±0.59
8 68.34 68.03 70.21 68.86±1.18
10 75.02 76.73 78.28 76.68±1.63
12 81.08 80.93 81.71 81.24±0.41
16 90.56 89.62 91.80 90.66±1.09
24 94.60 95.38 95.22 95.07±0.41
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Fig 6.31: In-vitro dissolution profile of BCF from F.M
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From the drug release data, it was evident that all the formulations gave an initial burst 
effect to provide the required loading dose of the drug. Also during  the  dissolution
process, a general  trend was observed   in all the formulations i.e, it was observed
that as the concentration of the polymer increased, there is a decrease in the drug release
rate. Except formulations (F12,F13,F14), all the formulations swelled radially and axially
and maintained physical integrity upto 24 hours.
In case of formulation F1, which was prepared by employing HPMC K100M (30%) as
the retarding polymer and sodium bicarbonate (25%) as the effervescent agent, the drug 
release was sustained upto 16 hours (94.77±0.76%). In order to further extend the release 
upto 24 hours, the concentration of HPMC K100M was increased to 40% in formulation
F2. Formulation F2 successfully sustained the drug release upto 24 hours (95.96±0.52%). 
Both the formulations were prepared with the same concentration of sodium bicarbonate
(25%) and compressed with the hardness of 7 kg/cm2. Both the the formulations
exhibited higher floating lag times even though sodium bicarbonate was used at high 
concentration. This may be due to the excess hardness of the tablets. Hence, the hardness
was reduced to 4 kg/cm2 in rest of the formulations.
Formulations F3-F6 were prepared using HPMC K100M at different concentrations 
(20%,25%,30%,40%) and the concentration of effervescent agent was maintained
constant (10%) in the formulations. Formulations F3-F6 sustained the drug release upto
10   hrs  (99.37±0.34%),  12  hrs  (96.53±0.88%),  16  hrs  (97.48±0.83%),  24  hrs 
(98.87±2.96%), respectively. For the formulations F3-F6, the release rate was more 
sustained with increasing concentration of the polymer. The reason may be attributed to
the increase in viscosity of the gel as well as the gel layer with longer diffusional path.
This could cause a decrease in effective diffusion coefficient of the drug and a reduction
in drug release rate. Formulation F6 successfully sustained the drug release upto 24 hours
(98.87±2.96%). In order to further improve the buoyancy lag time, F7 was formulated 
with increased concentration of effervescent agent (12.5%), and all other excipients were
same as in the formulation F6. Formulation F7 exhibited improved floating lag time and
exhibited same release rate as F6. The slight increase in the concentration of sodium
bicarbonate did not alter the release rate.
From the above findings, the concentration of the polymer and the effervescent agent
were optimized at 40% and 12.5% respectively. The same concentration of the polymer
and effervescent agent was used in rest of the formulations (F8-F14).
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Further an attempt was made to study the effect of low viscosity grades of HPMC on the
drug release rate. Formulations F8 and F9 containing HPMC K15M and HPMC K4M 
respectively sustained the drug release upto 16 hours(99.73±2.23%) and 10 
hours(95.76±0.75%) respectively. From the above findings, the retarding ability of the 
HPMC matrices was of the order.
HPMC K100M >HPMC K15M > HPMC K4M
The rate of drug release was found to be inversely related to the viscosity grade of HPMC 
present in the matrix structure i.e, higher the viscosity grade slower the drug release rate
from the  matrix.  The reason for this is higher viscosity induces  greater chain
entanglement than a polymer of low viscosity. Therefore, it is harder for longer chains to 
dissolve because of the high energy required for pulling them off the matrix. Thus, higher
viscosity polymers induce the formation of a thicker gel layer after hydration. As
discussed the effect of polymer viscosity was mainly due to the differences in their
molecular weights.
Formulations F10 and F11 were formulated using guar gum and xanthan gum 
respectively. Both the formulations successfully sustained the drug release upto 24 hours. 
Both the formulations showed the release of 98.70±1.96% and 98.47±0.71% respectively
in 24 hrs.
Formulations F12, F13 and F14 were formulated using different grades of PEO. Among 
the 3 formulations, F14 successfully sustained the drug release upto 24 hours. But, 
erosion in large extent was observed from these formulations. This may be due to the
water soluble nature of PEO leading to gradual erosion of the matrix and the formulations 
failed to maintain the physical integrity upto 24 hours. Moreover, these formulations also
failed to achieve buoyancy for the required period of time. Hence, these formulations
were rejected.
The marketed formulation F.M sustained the drug release upto 24 hours and showed the 
release of 95.07±0.41%.
6.3. Drug release kinetics and mechanism:
The rate and mechanism of release of Baclofen from the prepared floating tablets and the 
marketed formulation were analyzed by fitting the dissolution data into the zero-order,
first-order, Higuchi’s and Korsmeyer-Peppas equation.
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In case of zero order kinetics, the graph was plotted between cumulative percent of drug 
released versus time, and for first order release kinetics, the graph was plotted between
log cumulative percent of drug remaining versus time. For Higuchi model, the graph was
plotted between cumulative percent of drug released versus square root of time, and for
Korsmeyer-Peppas model, the graph was plotted between log cumulative percent of drug
released versus log time .The plots are shown in Figs.6.32-6.91.
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RESULTS AND DISCUSSION
Drug release kinetic profiles of formulation F1
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Fig 6.32: Zero order kinetic profile Fig 6.33: First order kinetic profile
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Fig 6.34: Higuchi kinetic profile Fig 6.35: Peppas kinetic profile
PGPCOPS & RI.  NAMAKKAL. Page 83
M
ea
n
%
 r
el
ea
se
d
M
ea
n
%
re
le
as
ed
M
ea
n
lo
g
%
un
re
le
as
ed
M
ea
n
lo
g
%
re
le
as
ed
RESULTS AND DISCUSSION
Drug release kinetic profiles of formulation F2
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Fig 6.36: Zero order kinetic profile Fig 6.37: First order kinetic profile
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Fig 6.38: Higuchi kinetic profile Fig 6.39: Peppas kinetic profile
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Drug release kinetic profiles of formulation F3
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Fig 6.40: Zero order kinetic profile Fig 6.41: First order kinetic profile
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Fig 6.42: Higuchi kinetic profile Fig 6.43: Peppas kinetic profile
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Drug release kinetic profiles of formulation F4
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Fig 6.44: Zero order kinetic profile Fig 6.45: First order kinetic profile
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Fig 6.46: Higuchi kinetic profile Fig 6.47: Peppas kinetic profile
PGPCOPS & RI.  NAMAKKAL. Page 86
M
ea
n
%
 r
el
ea
se
d
M
ea
n
%
re
le
as
ed
M
ea
n
lo
g
%
re
le
as
ed
M
ea
n
lo
g
%
un
re
le
as
ed
RESULTS AND DISCUSSION
Drug release kinetic profiles of formulation F5
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Fig 6.48: Zero order kinetic profile Fig 6.49: First order kinetic profile
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Fig 6.50: Higuchi kinetic profile Fig 6.51: Peppas kinetic profile
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Drug release kinetic profiles of formulation F6
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Fig 6.52: Zero order kinetic profile Fig 6.53: First order kinetic profile
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Fig 6.54: Higuchi kinetic profile Fig 6.55: Peppas kinetic profile
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Drug release kinetic profiles of formulation F7
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Fig 6.56: Zero order kinetic profile Fig 6.57: First order kinetic profile
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Fig 6.58: Higuchi kinetic profile Fig 6.59: Peppas kinetic profile
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Drug release kinetic profiles of formulation F8
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Fig 6.60: Zero order kinetic profile Fig 6.61: First order kinetic profile
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Fig 6.62: Higuchi kinetic profile Fig 6.63: Peppas kinetic profile
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Drug release kinetic profiles of formulation F9
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Fig 6.64: Zero order kinetic profile Fig 6.65: First order kinetic profile
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Fig 6.66: Higuchi kinetic profile Fig 6.67: Peppas kinetic profile
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Drug release kinetic profiles of formulation F10
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Fig 6.68: Zero order kinetic profile Fig 6.69: First order kinetic profile
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Fig 6.70: Higuchi kinetic profile Fig 6.71: Peppas kinetic profile
PGPCOPS & RI.  NAMAKKAL. Page 92
M
ea
n
%
 r
el
ea
se
d
M
ea
n
%
re
le
as
ed
M
ea
n
lo
g
%
re
le
as
ed
M
ea
n
lo
g
%
un
re
le
as
ed
RESULTS AND DISCUSSION
Drug release kinetic profiles of formulation F11
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Fig 6.72: Zero order kinetic profile Fig 6.73: First order kinetic profile
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Fig 6.74: Higuchi kinetic profile Fig 6.75: Peppas kinetic profile
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Drug release kinetic profiles of formulation F12
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Fig 6.76: Zero order kinetic profile Fig 6.77: First order kinetic profile
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Fig 6.78: Higuchi kinetic profile Fig 6.79: Peppas kinetic profile
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Drug release kinetic profiles of formulation F13
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Fig 6.80: Zero order kinetic profile Fig 6.81: First order kinetic profile
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Fig 6.82: Higuchi kinetic profile Fig 6.83: Peppas kinetic profile
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Drug release kinetic profiles of formulation F14
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Fig 6.84: Zero order kinetic profile Fig 6.85: First order kinetic profile
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Fig 6.86: Higuchi kinetic profile Fig 6.87: Peppas kinetic profile
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RESULTS AND DISCUSSION
Drug release kinetic profiles of Marketed formulation
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Fig 6.88: Zero order kinetic profile Fig 6.89: First order kinetic profile
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Fig 6.90: Higuchi kinetic profile Fig 6.91: Peppas kinetic profile
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The results of the regression analysis are summarized in Table 6.21.
Table 6.21: Release kinetic parameters for BCF SR floating formulations
Formulation
Zero order First order Higuchi Peppas plot
R2 K0(mg/hr) R
2 K(hr-1) R 2 KH(mg/hr
1/2) R2 n
F1 0.895 5.099 0.959 0.158 0.994 22.713 0.994 0.41
F2 0.843 3.554 0.976 0.119 0.987 19.458 0.992 0.42
F3 0.863 8.339 0.869 0.421 0.989 30.186 0.998 0.33
F4 0.890 6.667 0.940 0.235 0.988 26.246 0.961 0.34
F5 0.839 5.466 0.988 0.225 0.979 24.953 0.999 0.39
F6 0.824 3.745 0.970 0.150 0.976 20.632 0.983 0.37
F7 0.805 3.642 0.951 0.151 0.968 20.209 0.972 0.30
F8 0.881 5.989 0.961 0.253 0.986 26.762 0.977 0.45
F9 0.931 8.486 0.942 0.277 0.995 29.769 0.974 0.44
F10 0.691 3.480 0.988 0.206 0.914 20.246 0.999 0.29
F11 0.827 4.326 0.994 0.174 0.956 23.551 0.987 0.71
F12 0.958 7.786 0.979 0.228 0.980 29.428 0.993 0.67
F13 0.888 5.90 0.967 0.154 0.968 26.01 0.997 0.76
F14 0.754 3.830 0.970 0.142 0.939 21.631 0.988 0.55
F M 0.787 3.663 0.986 0.125 0.963 20.50 0.983 0.55
When the correlation coefficient ‘R2’ value of zero order and first order plots were 
compared, it was observed that the ‘R2’ values of zero order plots were in the range of
0.691 to 0.958 where as the ‘R2’ values of first order plots were in the range of  0.869
- 0.994. The ‘R2’ values of first order plots were found to be superior when compared to 
the zero order plots indicating drug release from all the formulations followed first
order kinetics ( drug release rate is dependent upon its concentration) suggesting the drug 
release in a sustained manner.
From the percent drug released versus square root of time plots, it was observed that the
‘R2’ values were found to be in the range of 0.914-0.995 for the formulations studied.
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The plots were linear  indicating the release of drug from these formulations was
governed by diffusion process.
To confirm the exact mechanism of drug release from these formulations, the dissolution 
data was fitted to Korsmeyer-Peppas equation. For the formulations (F3-F7, F10) the
release exponent ‘n’ was found in the range of 0.29-0.39. From the ‘n’ values, it was
evident that the release mechanism of these formulations cannot be predicted clearly by
the Power law as it appears to  be a complex mechanism of  swelling, diffusion and
erosion.
For the formulations (F1,F2,F8,F9) the release exponent ‘n’ was found in the range of
0.41-0.45, indicating Fickian diffusion as the drug release mechanism.
For the formulations (F11-F14) and the marketed formulation, the release exponent ‘n’
was  found  to  be  in  the  range  of  0.55-0.76 indicating  non-fickian (anomalous) 
diffusion as the drug release mechanism from these formulations i.e, diffusion coupled
with polymer relaxation.
6.4. Selection of the optimized formulation:
Based upon the buoyancy characteristics and percent cumulative drug release, the 
optimized formulation was selected. Formulation (F11) containing xanthan gum-40%,
sodium bicarbonate-12.5% exhibited a very less floating lag time of 20.33±6.03 seconds 
and total floating time of 24 hours (Fig.6.92). Formulation F11 released 98.47±0.71% of 
the drug in 24 hours. F11 showed better buoyancy characteristics and drug release profile 
when compared to other  formulations. Hence, it was selected as the optimized
formulation.
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A B C D 
A-At 0 seconds, B– At 20 seconds, C- At 23 seconds, D- After 24 hours
Fig. 6.92. Photographs taken during in-vitro buoyancy study of formula F11 in
900mL of 0.1 N HCl at different time intervals.
6.5. Comparison with the marketed product:
Optimised formulation F11 was compared with the marketed product.
Marketed product details:
BACLOF OD 20
BACLOFEN EXTENDED RELEASE (GRS) TABLETS 
Manufactured by:
INTAS PHARMACEUTICALS 
B.No. KL 0379
MFD.MAY 2010
EXP.APR.2012
Optimised formulation (F11) exhibited very less floating lag time of 20.33±6.03 seconds 
when compared to the marketed formulation (63.67±4.01 seconds). F11 showed a better
drug release profile than the marketed formulation by releasing 98.47±0.71% of the drug 
in 24 hours. The marketed formulation released 95.07±0.41% in 24 hours. Both the
formulations exhibited the total floating time of 24 hours. F11 was found to be superior
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RESULTS AND DISCUSSION
when compared to the marketed formulation. The release profiles of F11 and marketed
formulation are shown in Fig.6.93.
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40
20
0
0 4 8 12 16 20 24 28
Time ( hours)
Fig.6.93. Drug release profiles of F11 and marketed formulation
6.6. Determination of Similarity factor:
Similarity factor was calculated and it was found to be 51.60. The similarity factor is
within the acceptable limit (>50) which confirms the similarity between the release
profiles of F11 and the marketed formulation.
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SUMMARY AND CONCLUSIONS
Spasticity, a condition in which certain muscles are continuously contracted, affects over
12 million worldwide. Generally, spasticity is associated with common neurological 
disorders like multiple sclerosis, stroke, cerebral palsy and spinal cord injury. Baclofen is
the largest prescribed drug for this indication, world wide.
In the market, Baclofen is available as conventional tablets, orally disintegrating tablets
and  once-daily GRS tablets. Due to short elimination half-life (2.5-4 hours), the
conventional and orally disintegrating tablets need to be administered 3-4 times a day (for 
several days)leading to poor patient compliance and there is also increased incidence of
side effects with these formulations. The patient compliance can be improved and the side 
effects can be minimized with a once-daily sustained release formulation.
Absorption of the Baclofen is limited to stomach or upper part of the GI tract i.e, its 
absorption on arrival to colon (or even before) is low or nonexistent and therefore its 
bioavailability is incomplete when administered as a sustained release formulation. The 
bioavailability of the drug can be increased by making the drug completely absorbed in
the stomach by gastro-retentive drug delivery system. Even though once-daily extended
release GRS is available in the market (Baclof OD, INTAS pharmaceuticals), it is very
expensive as it is a coated multi-layer gas generating floating tablet.
Hence, in the present investigation, efforts were made to develop once-daily sustained
release gastro-retentive floating system of Baclofen which is cost effective.
The important objectives of the proposed research work are:
• Determination of solubility of BCF in 0.1N HCl.
• To develop suitable formulae and procedure for the manufacture of BCF sustained
release floating tablets in a relatively economical way.
• To characterize the in-situ interactions between the drug and other excipients, if
any by FT-IR examination.
• Determination of Pre-compression parameters of the powder blends of various 
formulations.
• To  formulate BCF SR floating matrix tablets  using  polymers like HPMC K4M
,HPMC K15M, HPMC K100M, Polyethylene oxide WSR-301, Polyethylene
oxide WSR-303 (Synthetic polymers) and Xanthan, guar gum (natural polymers) 
and sodium  bicarbonate as the effervescent  agent  by direct  compression
technique.
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• To evaluate the post compression parameters of the prepared tablets.
• In-vitro evaluation of the gastro retentive tablets for the buoyancy and release 
characteristics.
• To analyze the rate and mechanism of release of Baclofen from the prepared
floating tablets and the marketed formulation.
• Selection of the optimized formulation.
• Comparison of the optimized formulation with the marketed product.
• Determination of similarity factor.
Solubility study:
The dissolution medium employed for the gastro-retentive tablets is 0.1N HCl (pH-1.2) 
(Simulated gastric fluid). Hence, the solubility of Baclofen in 0.1N HCl was determined 
inorder to verify whether sink condition can be maintained in the in-vitro dissolution
process employing 0.1N HCl as the dissolution medium.
• Practically, the solubility of Baclofen in 0.1 N HCl (Simulated gastric fluid) was
found to be 25.2 mg/mL.
• From the solubility study, it was evident that the sink condition can be maintained
in the in-vitro dissolution process employing 0.1N HCl as the dissolution medium.
Drug- excipient compatibility study:
FT-IR spectroscopy was employed to ascertain the compatibility  between  the 
drug and the selected excipents.
• FT-IR spectrum of Baclofen showed the following characteristic peaks at
1093cm-1 (due to –C-Cl), 1526 cm-1 (due to -COOH), and 1626 cm-1 (due to –
NH2).
• These prominent peaks of drug were also present in the IR spectra of physical
mixtures of drug with various excipients, thus revealing compatibility of the 
selected drug with the excipients.
Determination of Pre-compression parameters  of the powder blends  of various 
formulations:
The powder blends of the formulations were evaluated for micromeritic properties like bulk
density, tapped density, Carr’s compressibility index and Hausner’s ratio.
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From the results, it was evident that the powder blends of all the formulations possessed
good  flow properties. Hence, direct compression technique was employed for the 
preparation of tablets.
Evaluation of BCF floating tablets:
The prepared BCF floating tablets were evaluated for the following parameters:
Post-compression parameters: The formulated tablets were evaluated for various 
physico-chemical parameters like hardness, weight variation, friability, drug content 
uniformity.
• Hardness: The hardness of the formulations ranged between 4 – 7 kg/cm2. No
significant difference in hardness values of all batches of tablets prepared was 
observed. So, all the formulations pass the test.
• Weight variation: The weight variation for all the formulations was found to be
within the limit (7.5% deviation).
• Friability: A maximum weight loss of not more than 1% of the tablet weight
during the friability test is generally considered acceptable. The friability of all the
tablets was within the limit (0.21%–0.80%).
• Drug content uniformity: From the results, the percentage of BCF in all the 
formulations ranged from 95.53±1.39%  – 101.4±0.52%. So, all the tablet 
formulations were found to possess the claimed amount of the drug.
In-vitro Buoyancy study:
The study was performed using USP XXI type-II (paddle) dissolution apparatus 
containing 900mL of 0.1N HCl as the dissolution medium. The study was performed at 
the paddle rotational speed of 50 rpm and a temperature of 37±0.5°C.The floating lag
time and the total floating time were recorded by visual observation using a stop watch.
• From the Buoyancy study, it was evident that hardness of the formulation greatly 
influences the buoyancy lag time. It was found that optimum hardness for the 
formulation of effervescent tablets is 4 kg/cm2. Further increase in the hardness, 
drastically increased the floating lag time (F1,F2).
• It was observed that with the increase in the polymer concentration with same 
concentration of sodium bicarbonate in the formulations (F3-F6), the floating lag
time increased gradually.
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• With formulations containing the same amount of polymer of the same grade
(F6,F7), floating lag time decreased with the increase in concentration of sodium
bicarbonate.
• Formulations F9 and F10 containing HPMC K4M  and Guar gum respectively
exhibited very high floating lag times. Hence, these formulations were rejected.
• The duration of buoyancy of all the formulations (including marketed product)
was found to be 24h except for the formulations (F12,F13,F14) which were 
formulated  using different grades of PEO. The formulations also failed to 
maintain the physical integrity upto 24 hours. Hence, it was evident that PEO is
unsuitable for the formulation of floating tablets.
• The buoyancy lag time of all the formulations (including marketed product)
ranged between 14.67±1.16–584±14.42 seconds. Formulation F3 prepared using
HPMC K100M-20% and sodium bicarbonate-10% exhibited very less floating lag 
time (14.67±1.16 seconds) and formulation F9 prepared using HPMC K4M-40% 
and  sodium  bicarbonate   12.5%,  exhibited  very  high  floating  lag  time
(584±14.42seconds).
From the Buoyancy study, it was concluded that optimum amount of sodium bicarbonate
and polymer with sufficient gel strength are essential to achieve optimum in-vitro
buoyancy.
In-vitro drug release study:
In-vitro dissolution study was carried out for all the batches of matrix tablets using 
USP XXI type-II (paddle type) dissolution apparatus at temperature 37 + 0.5°C and 50
rpm speed. 900 mL of 0.1N HCl was used as the dissolution medium.
• From the drug release data it was evident that, all the formulations gave an initial
burst effect to provide the required loading dose of the drug.
• A  general  trend  was  observed  in  all  the formulations i.e it was observed
that as the concentration of the polymer increased, there is a decrease in the drug
release rate (F3-F6).
• The rate of drug release was found to be inversely related to the viscosity grade of
HPMC present in the matrix structure i.e, higher the viscosity grade slower the
drug release rate from the matrix. The retarding ability of the HPMC matrices was
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of the order.
HPMC K100M >HPMC K15M > HPMC K4M
• Except formulations (F12,F13,F14) all the formulations swelled radially and
axially and maintained physical integrity upto 24 hours. In the formulations 
prepared using different grades of PEO (F12,F13,F14), erosion in large extent was
observed. Moreover, these formulations also failed to achieve buoyancy for the 
required period of time. Hence, these formulations were rejected.
• Formulations  prepared  using  polymers  HPMC  K100M  (F2,F6,F7),  Guar 
gum(F10), Xanthan gum(F11) at a concentration of 40% and effervescent agent-
12.5% and the marketed formulation successfully sustained the drug release upto
24 hours and exhibited total floating time of 24 hours by maintaining the physical
integrity upto 24 hours.
Drug release kinetics and mechanism:
The rate and mechanism of release of BCF from the prepared floating tablets and the 
marketed formulation were analyzed by fitting the dissolution data into the zero-order,
first-order, Higuchi’s and Korsmeyer-Peppas equation.
• The ‘R2’ values of first order plots were found to be superior when compared to
the zero order plots indicating drug release from all the formulations followed
first order  kinetics ( drug release rate is dependent upon its concentration)
suggesting the drug release in a sustained manner.
• The percent drug released versus square root of time plots were linear with the
‘R2’ values ranged between 0.914–0.995 indicating the release of drug from these 
formulations was governed by diffusion process.
• To confirm the exact mechanism of drug release from these formulations, the 
dissolution data was fitted to Korsmeyer-Peppas equation. For the formulations
(F3-F7, F10) the release exponent ‘n’ was found in the range of 0.29–0.39. From
the ‘n’ values, it was evident that the release mechanism of these formulations
cannot  be predicted clearly by the  Power law as it appears to be a complex
mechanism of swelling, diffusion and erosion.
• For the formulations (F1,F2,F8,F9) the release exponent ‘n’ was found in the
range of 0.41-0.45, indicating Fickian diffusion as the drug release mechanism.
For the formulations (F11-F14) and the marketed formulation, the release
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exponent ‘n’ was found to be in the range of 0.55-0.76 indicating non-fickian 
(anomalous) diffusion as the drug release mechanism from these formulations i.e, 
diffusion coupled with polymer relaxation.
Selection  of  the  optimized  formulation  and   comparison   with  the  marketed 
formulation:
Formulation (F11) containing xanthan gum-40%, sodium bicarbonate-12.5% exhibited a 
very less floating lag time of 20.33±6.03 seconds and total floating time of 24 hours and
released 98.47±0.71% of the drug in 24 hours. Hence, it was selected as the optimized
formulation. Marketed formulation exhibited FLT of 63.67±4.01 seconds, TFT of 24 
hours and released 95.07±0.41% drug in 24 hours. F11 was found to be superior when 
compared to the marketed formulation.
Determination of Similarity factor:
Similarity factor was calculated and it was found to be 51.60. The similarity factor is
within the acceptable limit (>50) which confirms the similarity between the release
profiles of F11 and the marketed formulation.
Conclusion: Finally, once-daily sustained release gastro-retentive floating tablets of
Baclofen were successfully formulated in a relatively economical way when compared to 
the marketed  formulation and found to be superior when compared to the  marketed
formulation.
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